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ABSTRACT OF THESIS 
 
 
Comparing the Quantitation of Opiates from Possible Drug Overdose Cases Using 
Results of Blood Analysis and Liver Analysis 
 
 
Currently the quantitation of opiates at the Erie County Medical Examiner’s 
Office Toxicology Laboratory is conducted through whole blood analysis. The objective 
of this thesis project was to determine if the analysis of opiates could be conducted 
through liver analysis, and if the analysis of opiates would provide a more accurate 
quantitation compared to the blood analysis. The quantitation of opiates was conducted 
from the livers of sixty-four possible overdose cases that were brought into the Erie 
County Medical Examiner’s Office between 2013 and 2015. Results showed that the 
opiate drugs could successfully be quantitated using the liver analysis. Generally the data 
showed there to be quantitatively more drugs measured in the liver in comparison to the 
blood. The liver is the primary site for the metabolism of toxins in the body, and results 
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Sixty four cases from the Erie County Medical Examiner’s Office were chosen for 
this thesis study based on an initial suspicion of opiate overdose. If the case tested 
positive for opiates during the immunoassay screening process, a detailed blood analysis 
is conducted to determine the quantitation of opiates present in that individual at the time 
of autopsy. A liver analysis was conducted on these sixty four cases in order to determine 
if the liver quantitation provides more accurate opiate concentration than measured in the 
blood.  
Every death that gets reported to the Medical Examiner’s Office (e.g. accidents, 
suicides, homicides, etc.) receives a toxicology screen that consists of a blood-alcohol 
test and three presumptive tests for drugs; an oxycodone/oxymorphone direct enzyme-
linked immunosorbent assay (ELISA) blood kit test, a basic drug screen from the gas 
chromatograph mass spectrometer (GC/MS), and an acid neutral screen from the liquid 
chromatograph dual mass spectrometer (LC/MS/MS) (Erie County Department of Health, 
2015).  
Analysis of volatiles, which includes the quantitation of ethanol, methanol, 
isopropanol and acetone, is done in each case. The screening method uses a headspace 
gas chromatograph to analyze these volatiles and semi-volatile organics which may be 





possible presence of amphetamine, benzodiazepines, buprenorphine, cannabinoids, 
carisoprodol, cocaine metabolite, fentanyl, methadone, opiates, oxycodone, 
sympathomimetics and zolpidem.  
The basic drug screen conducted through the GC/MS detects about 40 basic drugs 
with a pH > 7, and the acid neutral drug screen detects acidic and neutral drugs (pH ≤ 7). 
The Erie County Medical Examiner’s Office Toxicology Lab has been working toward 
incorporating a Xevo G2-XS Time of Flight (Tof) instrument by Waters technology to 
identify and confirm compounds in samples (Waters, 2016). The instrument has about 
3,000 compounds in its database that it is capable of identifying. When the instrument is 
successfully in analyzing samples the Toxicology Lab hopes to replace both the basic, 
acid, and neutral screening tests with the Xevo G2-XS Tof (Private conversation with C. 
Corcoran, Toxicologist, Erie County Medical Examiner’s Office, March 16, 2016). 
Any positive tests that result from these presumptive tests must go through 
confirmatory and qualitative analysis. Results from the presumptive drug screens will 
determine which samples will be tested for further confirmation and quantitation. If the 
quantitation test is negative, then the result of those drugs are “non-detected,” and if the 
quantitation results are over the limit of detection then the quantitation analysis confirms 
the presence and concentration of those drugs (Private conversation with C. Corcoran, 
Toxicologist, Erie County Medical Examiner’s Office, March 16, 2016). 
Currently, the quantitation of opiates in the blood is conducted through 
LC/MS/MS. Specifications of the extraction procedure and the LC/MS/MS are listed in 





(plasma and serum). The opiate drugs currently tested in the Erie County Toxicology lab 
include morphine, morphine-3-glucuronide, morphine-6-glucuronide, 6-
monoacetylmorphine (6-MAM), hydromorphone, oxymorphone, codeine, hydrocodone, 
oxycodone, fentanyl, norfentanyl, buprenorphine, norbuprenorphine, also naloxone. 
Many opiate drugs are commonly used as pain medication. Opiate drugs are 
generally called “opiates” because they can be derived from opium or from chemical 
derivatives (International Narcotics Control Board, 2007). “Opioid” is a general term for 
natural and synthetic drugs similar to morphine but not necessarily similar in chemical 
structure (International Narcotics Control Board, 2007).  
According to Figure 1 the consumption of opioids, opiates and synthetic opioids 
has significantly increased from 1994-2013, simultaneously there has been an increase in 
the abuse of prescriptions drugs which have related to some overdose deaths in those 








Figure 1. Displays the daily doses of opioid consumption calculated from countries 
around the world calculated from the International Narcotics Control Board for 2013.  
a 
Opioids: opiates and synthetic opioids 
b
Opiates: Including buprenorphine, an opiate controlled under the Convention on 
Psychotropic Substances of 1971 
c
Synthetic Opioids: Including pentazocine, a synthetic opioid controlled under the 
Convention on Psychotropic Substances of 1971 






Morphine and codeine are natural alkaloids which can be extracted from the raw 
materials of the poppy plant, Papaver somniferum; these raw materials consist of opium 
and poppy straw (International Narcotics Control Board, 2007). Morphine acts on the 
central nervous system to decrease the feeling of pain.  
Heroin, also known as 3, 6-diacetylmorphine, or “diamorphine,” is a derivative of 
morphine formed through acetylation. Heroin was derivatized from morphine in the hope 
of producing a drug with reduced the physical dependence compared to morphine, and 
with increased analgesic effects (Bedford, 1991). Although the analgesic effects were 
much stronger than morphine, the physical dependence from using the drug was 
increased much more as well (Bedford, 1991). The highest number of deaths are from 
opiate substance abuse according to a study conducted in 2013 (GBD 2013 Mortality and 
Causes of Death Collaborators, 2014). Figure 2 displays the most dangerous drugs which 







Figure 2. The comparison of dangerously addictive various drugs are generated from 
information by medical psychiatrists who specialize in addiction treatment (Nutt, 2007). 
 
Codeine is an opiate used to treat pain, diarrhea and for use as a cough 
suppressant. Although it is a natural alkaloid most of the time it is created through a 
semi-synthetic process using morphine (International Narcotics Control Board, 2007). In 
2010-2013 it was labeled as one of the most commonly used narcotic drugs among the 
world through dosage and the number of countries it was used in (International Narcotics 
Control Board, 2014). 
Codeine is usually ingested and is converted into morphine by the cytochrome 





medications are inhibitors of this enzyme, such as Paxil, Prozac, Benadryl, and can block 
the conversion of codeine to morphine while other drugs if present in the body 
simultaneously, may speed up the conversion of codeine into morphine (Srinivasan, 
1997).  Codeine and its metabolites are mostly excreted from the body through the 
kidneys (DataPharm, 2015).  
 
 
Figure 3. The chemical structure of morphine, codeine, and heroin, respectively 
(Bedford, 1991). 
 
Diamorphine (“heroin”) is a Schedule 1 drug in the U.S., in order to possess it 
legally one must have a license provided by the Drug Enforcement Administration (U.S. 
Department of Justice Drug Enforcement Administration, 2015a). The punishable 
sentence of possessing over 100 grams of diamorphine, or a mixture of diamorphine 
could be more than 5 years federal imprisonment.  
 According to the most recent statistics, India is the major manufacturer of licitly 
produced of opium. The bulk of opium exported to other countries is used for the 
extraction of alkaloids while some countries use prepared opium for medicinal purposes 





produced opium, the U.S. acquires most of its heroin illegally from Mexico and 
Colombia through Mexican criminal cartels (International Narcotics Control Board, 
2014; Yucatan Times, 2014).  
Diamorphine can be administered in the body orally, intravenously, by smoking, 
snorting or as a suppository. Administering the drug orally is the least popular method 
since the diamorphine becomes completely metabolized into morphine through first-pass 
metabolism in the liver and gut wall, greatly reducing the bioavailability of the drug and 
the physical effects (Rowland, 1972).  
Injecting heroin in the body is the most popular method of use and is the fastest 
route of administration. When administered in the body intravenously, heroin is 
metabolized in the blood immediately into 6-monoacetyl morphine, also called 6-MAM 
(Baselt, 2011; Bedford, 1991). Diamorphine’s first metabolite, 6-MAM can be found 
more concentrated in the skeletal muscle, kidney, lung, liver and spleen before showing 
up in the blood (DataPharm, 2013). However, in an overdose death, neither 6MAM or 
heroin can be detected in post-mortem tissue unless the heroin was administered in the 
body very close to the time of death (Bedford, 1991). The half-life of morphine is 2-3 
hours and the half-life of diamorphine is 2-6 minutes (DataPharm, 2013). This is one 
reason why 6-MAM was difficult to quantitate during this project. Once the 6-MAM 
crosses the blood-brain barrier, which separates circulation blood from brain extracellular 
fluid in the central nervous system so it can react with opiate receptors, it gets 
metabolized into morphine through hydrolysis (Baselt, 2011). Then morphine is carried 
to the liver where it is broken down through first-pass metabolism. About 40-50% of the 





morphine forms conjugates with glucuronic acid by the phase II metabolism enzyme 
UDP-glucuronosyl transferase-2B7, forming about 60% morphine-3-glucuronide and 
about 6-10% morphine-6-glucuronide leading to the formation of morphine-3,6-
diglucuronide as shown in Figure 4 (Bedford, 1991; DataPharm, 2013; Mandal, 2013).  
Morphine can also be metabolized into, normorphine, codeine and 
hydromorphone while in the body, but in much smaller concentrations; shown in Figure 5 
(Mandal, 2013). The majority of what started as heroin is excreted from the kidneys as 
morphine and its glucuronide metabolites in urine (DataPharm, 2013; Mandal, 2013). 
About 7-10% of the drug is eliminated through the liver, gallbladder and bile ducts, while 
about 35% of the morphine component remains bound to human plasma proteins 
(DataPharm, 2013). If death occurs shortly after administering the drug, the concentration 
of morphine and its metabolites in the liver may be low; however, if levels in the liver 
and bile are higher than the blood concentration it’s possible that the individual had a 
prolonged survival time (Bedford, 1991). 
Morphine can also be administered in the form of tablets or capsules, rectally, 
intravenously, subcutaneously, inhaled, or snorted in powder form. Morphine itself is a 
highly addictive opioid often used in the medical field for surgery and pain relief. Once 
administered in the body, morphine is absorbed into the bloodstream and is metabolized 
as previously stated: morphine is primarily broken down in the liver and glucuronidated 
by the phase II metabolism enzyme to form its metabolites, and some may get stored in 
fat, where it may be detected after a long period of time and sometimes until death. The 
length of time these drugs remain in fat cells depends on different characteristics of that 





for morphine is about 120 minutes, and then it’s usually excreted in through the urine in 
the form of a metabolite (Mandal, 2013).  
Drug concentrations recorded from the autopsy may not reflect the accurate drug 
concentrations from that individual at the time of death due to postmortem redistribution 
(PMR). PMR is the distribution of drugs to the surrounding tissues after death and may 
occur through a number of mechanisms such as diffusion through blood vessels or 
through diffusion of organ cavities to surrounding organs. Many of the effects of PMR 
are still unknown, and different drugs react differently; but in many cases, drug 
concentration, volume of drug distribution and the temperature of the corpse may 
influence the mechanism of PMR (Pélissier-Alicot, 2003). Many cases have shown drugs 
in the stomach and gastrointestinal tract to diffuse to the lower lobe of the left lung, the 
left kidney and the left posterior section of the liver; therefore doctors tend to sample the 
right sides of organs during an autopsy since they may be less prone to PMR. According 
to the Doctors at the Erie County Medical Examiner’s Office, all the liver samples 
collected from autopsy; including all the samples used in this project, are obtained from 
the right lobe of the liver unless physical effects prevent the occurrence of this procedure. 
Drugs that may be present in the liver, such as opiates, may often become redistributed 
through the hepatic veins to right chambers of the heart and its surrounding blood vessels, 
which may cause the drug concentration to decrease in the hepatic lobes which may 
contribute to the difference in drug concentration in the different sampling sites 













Figure 5. Metabolic pathways for morphine, codeine and heroin (Reisfield, 2007). 
 
Morphine, oxymorphone, oxycodone, fentanyl, and hydromorphone are all 
schedule II controlled opioid agonists due to their high risk for abuse and increased risk 
of respiratory depression which may result in death (Drugs.com, 2014).   
Hydromorphone is a derivative of morphine, containing a ketone formed through 
the hydrogenation. Both structures are shown in Figure 6. Hydromorphone is another 
analgesic drug that is commonly administered orally and gets absorbed in the 
gastrointestinal tract shortly after ingestion. It undergoes first-pass metabolism where it 
binds to opioid receptors in the brain and spinal cord (Drugs.com, 2014). About 8-19% of 
the hydromorphone is bound to plasma proteins, but most is metabolized in the liver 





metabolized into hydromorphone-3-glucuronide, some gets metabolized into 6-hydroxy 
reduction metabolites, and a small amount is unchanged hydromorphone before being 
excreted in the urine (Drugs.com, 2014).  
 
                                       
Figure 6. Morphine can become synthesized into hydromorphone. 
 
Hydrocodone can be semi-synthesized from codeine as shown in Figure 7. As 
previously stated, codeine is generally obtained from the poppy plant through an 
extraction process. The opioid pain medication hydrocodone is a schedule II substance in 
the U.S. and is generally prescribed to be taken orally. Some studies discovered 
hydrocodone to be stronger than codeine at binding to opioid receptors, but only one-
tenth as potent as morphine; although, it has been measured that hydrocodone to be about 
half as strong as morphine in its analgesic properties (Davis, 2005). In the liver, the 
hepatic cytochrome P450 enzyme CYP2D6 metabolizes hydrocodone into 
hydromorphone, and CYP3A4 converts hydromorphone into its other major metabolite, 
norhydrocodone through catalyzed oxidation as shown in Figure 8 (Vuilleumier, 2012). 
hydrocodone is metabolized into other minor metabolites as well, and 40% of 
hydrocodone is metabolized through non-cytochrome-catalyzed reaction (Vuilleumier, 





it was excreted through urine as the norhydrocodone metabolite compared to the 
concentration excreted as unchanged hydrocodone, and even less was excreted as the 
hydromorphone metabolite (Valtier, 2012). 
 
 
Figure 7. Hydrocodone is a semi-synthetic opioid derived from codeine.  
 
 
Figure 8. Hydrocodone and its metabolites; hydromorphone, and norhydrocodone, 
formed from the hepatic cytochrome P450 enzyme. 
 
Oxymorphone is produced commercially from the chemical, thebaine, which is 
acquired from the poppy plant. Oxymorphone, as well as hydromorphone, hydrocodone, 
oxycodone and actelymorphine, can be prepared from solutions of codeine, morphine or 
dionine by using palladium or platinum catalyst shown in Figure 9 (German Patent, 
1936). This method is much easier than the alternative method of using hydrogen gas to 
form the target compound. Oxymorphone can be administered by parenteral injection, 





effects as it has a higher affinity for μ-opioid receptors than morphine does (Prommer, 
2006). Oxymorphone’s bioavailability is about 10% if taken orally and about 20-40% of 
the compound binds to protein (Prommer, 2006). Oxymorphone is metabolized in the 
liver through a hepatic metabolism mechanism (Prommer, 2006). The drug concentration 
is greatly reduced before it reaches systemic circulation, and forms conjugates with 
glucuronic acid which converts it to oxymorphone 3-glucuronide and 6-OH-
oxymorphone before being excreted in the urine (Prommer, 2006).  
 
 
Figure 9. Procedure for the production of dihydromorphinones acquired from a German 
Patent in 1936 (German Patent, 1936).  
 
Oxycodone is another semi-synthesized opioid from thebaine shown in Figure 10 
(MedChemPedia, 2015). Oxycodone can be administered orally, rectally, or via 
parenteral or intranasal administration; however, in the United States, oxycodone is 
medically approved for oral administration only due to its high abuse potential when 
administered through other methods (Stoops, 2010).  OxyContin is a common name brand 
of oxycodone that supplies the drug in a controlled-release tablet form (Purdue Pharma 





about 60-87%, and intranasal bioavailability is about 46% (Analgesic Expert Group, 
2007).  
As most opioids, oxycodone acts on the μ-opioid receptors, a class of opioid 
receptors that has a high affinity for peptides involved in regulating the sensory nervous 
system’s response to potentially harmful stimuli, and produces effects that are typical of 
μ-opioid agonists such as euphoria, increased relaxation, and anti-anxiety (Purdue 
Pharma LP, 2016).  
Oxycodone is metabolized in the liver by the cytochrome P450 enzyme CYP2D6, 
which is one of the primary enzymes involved in the metabolism of xenobiotics in the 
body. From there, oxycodone is metabolized into a major metabolite; oxymorphone, 
which in turn, is more potent opioid agonist with stronger/higher binding affinity to μ-
opioid receptors compared to oxycodone (Purdue Pharma LP, 2016; Wang, 2009). 
Although oxymorphone has more analgesic properties, when transformed from the initial 
state of oxycodone, it has only shown to be present in small concentrations in the plasma 
and usually gets metabolized further into oxymorphone 3-glucuronide and 
noroxymorphone (Purdue Pharma LP, 2016).   
People taking CYP2D6 inhibitors or have slow metabolism are at risk of toxicity 
if not careful administering oxycodone (Purdue Pharma LP, 2016). Other metabolites 
produced from hepatic mechanisms of oxycodone include: noroxycodone, α- and ß-
oxycodol, noroxycodol and oxymorphol (Purdue Pharma LP, 2016). Finally, oxycodone 
and its metabolites are excreted from the body via the kidney. Free and conjugated 





free oxymorphone was less than 1%, conjugated oxymorphone was 10%, free and 
conjugated noroxymorphone was measured to be about 14% in the urine (Purdue Pharma 




Figure 10. Synthesis of thebaine (MedChemPedia, 2015). 
 
Fentanyl is also used for pain relief as it is a strong μ-opioid agonist and a very 
potent opioid analgesic with rapid onset of effects. Fentanyl is about 100 times more 
potent than morphine and generally only used in small doses, for example 100 





1990s, fentanyl patches have been prescribed to patients for a controlled release of the 
drug into the body (Current, 2007; International Narcotics Control Board, 2007). 
Fentanyl is available for administration into the body in various forms: 
intravenously, via lozenges, buccal tablets, which are meant to be held between the cheek 
and gum and dissolve slowly through the oral mucosa; nasal spray, inhaled spray, and as 
active transdermal patches. Fentanyl has high lipophilicity and low water solubility which 
allows it to penetrate the central nervous system more easily via the brain, spinal cord and 
other tissues. When administered trans dermally (via dermal patch), fentanyl has a 
distribution time of about 6 minutes with a 60-minute calculated redistribution time, and 
the half-life elimination is about 16 hours (Mayes, 2006). When administered 
intramuscular drug effects start within 7-8 minutes, and trans mucosal (via buccal tablet) 
drug effects start within 5-15 minutes. A trans mucosal administration has a 50% 
bioavailability of the total concentration and a transdermal patch will continue to release 
a concentration over the course a few days, depending on the dosage (PremierTox 
Laboratory, 2015).  
Shortly after administered trans dermally, the drug will move into loose 
connective tissues and skeletal muscles before it gets discharged into the bloodstream. 
When fentanyl is administered intravenously, drug effects are nearly immediate, and the 
drug concentration may be increased in the kidneys, lungs spleen, heart and possibly the 
brain (Mayes, 2006). Change in pH has shown to vary the distribution of fentanyl 
between the central nervous system and plasma; its binding capacity in the plasma 
proteins is generally 80-86%. Fentanyl has a high first-pass clearance effect during the 





dealkylation via the CYP3A4 enzyme where it becomes fentanyl’s primary metabolite, 
norfentanyl, shown in Figure 11.  
According to the pharmacology research conducted by Mayes in 2006, 
norfentanyl and other metabolites that are formed have minimal pharmacological activity 
in the body and become excreted through the urine and bile. Following a trans mucosal 
dose, about 0.4-6% fentanyl and 26-55% norfentanyl gets excreted from the body shortly 
after administration (PremierTox Laboratory, 2015). Following an intravenous 
administration of fentanyl, about 75% of the drug is excreted in the urine with about 10% 
unchanged fentanyl, and about 9% may be excreted from the bile as metabolites of 
fentanyl (Mayes, 2006).  
 
 
Figure 11. Fentanyl and its metabolism into norfentanyl (PremierTox Laboratory, 2015). 
 
Buprenorphine is also a semisynthetic opioid derivative of thebaine, shown in 
Figure 10. Buprenorphine is about 20-40 times more potent than morphine and is 
considered a Schedule III drug in the U.S. because its potential for abuse is less than 
schedule I and II (PremierTox Laboratory, 2015; U.S. Department of Justice Drug 
Enforcement Administration, 2015b). Buprenorphine is an analgesic with mixed agonist 





(International Narcotics Control Board, 2007; PremierTox Laboratory, 2015). It was used 
for that purpose in more than 40 countries in 2013 (International Narcotics Control 
Board, 2007). 
According to information from PremierTox laboratory in 2015, buprenorphine 
can be administered orally, via transdermal patch or parenteral injection. Sublingual 
administration has a bioavailability of about 51%, and a buccal film has a bioavailability 
of about 28%. Buccal films may appear as a rectangular film that’s manufactured to 
adhere upon contact with the moist buccal mucosa in order for the drug to be absorbed 
orally in the inner cheeks and lips. According to laboratory findings, after a 2 mg 
sublingual dose, the highest plasma concentration was reached after 1.3 hours, and the 
drug had a half-life of about 18-49 hours. A similarly studied intravenous dose of 0.3 mg 
buprenorphine reached its highest concentration in the plasma after 2 minutes, and it had 
a half-life of 2-4 hours (PremierTox Laboratory, 2015).  
Buprenorphine, like most of the other opioids, is metabolized in the liver by 
cytochrome P450 enzyme CYP3A4 where it’s converted into norbuprenorphine by N-
dealkylation (PremierTox Laboratory, 2015). Figure 12 shows the N-dealkylation of 
buprenorphine into norbuprenorphine.  
Norbuprenorphine is the major metabolite of buprenorphine and it’s a full agonist 
of μ, δ, and κ opioid receptors which help induce analgesic properties (Brown, 2012). As 
previously stated, μ-opioid receptors are a class of opioid receptors that has a high 
affinity for peptides involved in regulating the sensory nervous system’s response to 





coupled receptors that bind the guanine (“G”) nucleotides guanine diphosphate (GDP) 
and guanine triphosphate (GTP); and when activated, produce analgesic effects, although 
there is still much unknown about the details of how exactly the δ receptor responds this 
way (Varga, 2004). The κ opioid receptors help bind opioid-like compounds in the brain 
which helps produce the effects of these compounds. Such effects include the alteration 
of pain perception, mood, and motor control.  Norbuprenorphine tends to have more 
effects of respiratory depression, and less effectiveness of blocking pain sensory neurons. 
It has been suggested that norbuprenorphine’s effects may be due in part to its high 
affinity for the P-glycoprotein substrate (permeability glycoprotein), a protein in the cell 
membrane that pumps foreign substances or toxins out of cells, as well its lack of blood-
brain-barrier penetration (Brown, 2012).  
After about 6-11 days, about 95% of a dose of buprenorphine gets excreted from 
the body from the bile and kidneys. About 68% is excreted in the feces, and about 27% 
gets excreted in the urine; about 9.4% of the drug is excreted as buprenorphine 
glucuronide, and about 11% gets excreted as norbuprenorphine glucuronide (PremierTox 







Figure 12. Synthesis of buprenorphine into norbuprenorphine. 
 
Opioids tend to be highly addictive substances, and can have additional side 
effects such as constipation, nausea, vomiting, dizziness, dry mouth and drowsiness. 
Most times these drugs can be dangerous if they are combined with other drugs or 
alcohol. The use of opioids can lead to chemical dependence and withdrawal.  
Many times post mortem interpretation of opiates is complicated by the drug 
tolerance that is built up by the individuals that sometimes these addicts are capable of 
surviving up to ten times the normal lethal dose (Bedford, 1991). Known toxicity levels 






Table 1. Toxicity levels in opioids (Baselt, 2011). 
 
Toxic levels (mg/L) Half-life (t ½) 
 
Blood Liver Kidney Urine Bile  
      
 




1.3 – 6.7 Hours 





Heroin 0.38 0.35 0.7 0.49 
 
2 – 6 Minutes 
6-Monoacetylmorphine 0.01-3 
    
6 – 25 Minutes 
average 0.43 
    
 
Hydromorphone 0.02-1.2 0.07-7.7 0.1-5.2 1-29 1-20 
3 – 9 Hours 
 (Intravenous or normal release) 
10 – 22 Hours  
(Extended release) 
average 0.3 1.4 1.2 8.6 9.2  
Oxymorphone 0.03-0.12 
    
4 – 12 Hours 
Codeine 1.0-8.8 0.6-45 2.3-36 29-229 5.0-43 1.2 – 3.9 Hours 
average 2.8 6.8 12 104 18  
Hydrocodone 0.12-3.6 
    
3.4 – 8.8 Hours 
average 0.53 
    
 
Oxycodone 0.1-8.0 
    
3 – 6 Hours 
average 1.2 
    
 
Fentanyl 0.03-0.28 0.059-0.78 0.061-0.42 0.05-0.93 
 
3 – 12 Hours 
average 0.083 0.37 0.18 0.28 
 
 
Buprenorphine 0.011-0.29 0.04-2.73 0.081-1.38 0.04-10.33 
 
2 – 4 Hours (Parenteral) 
18 – 49 Hours (Sublingual) 












The quantitation of opiates in the blood is conducted through whole blood 
analysis at the at the Erie County Medical Examiner’s Office Toxicology Laboratory. 
The objective of this thesis project was to find out if the analysis of opiates could be 
conducted using the liver from case samples, and if the analysis of these components 
could provide more accurate quantitation of those drugs than in the blood analysis. If the 
analysis proves more successful compared to quantitation from blood analysis, it is 
possible the Erie County Toxicology Laboratory would consider using livers from case 







Methods & Results 
 
3.1 Prepare Liver Dilutions and Standards  
The first part of this project involved preparing the liver dilution samples and 
controls. All the livers used in this project were stored in a freezer unit kept at -21°C. The 
case livers were collected at time of autopsy then also stored in the freezer. A 1:3 liver 
homogenate was created using the case liver measured by taking five grams of liver, 
adding it to ten milliliters deionized water and using the homogenizer to slurry the 
mixture (Appendix I). Using the 1:3 homogenate we created multiple dilution samples 
(1:6, 1:9, 1:15, 1:30 and 1:60) using the liver matrix and whole sheep blood. Whole sheep 
blood was used in this project because it is more readily available than human blood and 
provides a similar biological matrix. Each sample was one milliliter in volume. The 1:3 
dilution was used as is; a half a milliliter 1:3 homogenate and half a milliliter whole 
blood was combined to make the 1:6 dilution; 0.33 mL combined with 0.67 mL whole 
blood to make 1:9 dilution. To make the 1:15 dilution, two milliliters of 1:3 homogenate 
was added to a ten volumetric flask then filled with whole blood. The 1:30 dilution was 
then made by taking half a milliliter of 1:15 dilution and adding half a milliliter of whole 
blood. Finally 0.25 mL of 1:15 dilution was combined with 0.75 mL whole blood to 
make the 1:60 liver dilution.   
For the first extraction conducted, we used a case liver from the morgue that was 
negative for opiates and fortified it with known concentration of opiates in order to prove 





liver dilutions were prepared as one milliliter samples, known concentrations of opiates 
were added to the samples using the working stock solutions “A,” “B,” and “C.” The 
concentration values for working stock solutions A, B & C have been listed in Table 2 of 
the Reagents & Materials section in Appendix II. The working stock solutions used in 
this procedure are the same used for routine opiate extraction/analysis of blood samples 
at the Erie County Toxicology Lab. 
After the third extraction performed for the extraction of opiates in the case livers, 
beef liver was used to make up the liver control samples, as it was more readily available 
and provided similar results to human liver. The beef liver used to make the liver 
dilutions was also stored in the freezer below -21°C. Once the procedure was established 
to further analyze all the case samples; low, medium, and high controls of a 1:9 beef liver 
dilution were always used as well as a negative 1:9 liver control sample. The liver 1:9 
dilutions were prepared first, then specific opiate concentrations listed in Table 22 of 
Appendix III were added to the liver samples to create the low, medium and high liver 
controls. In addition to the liver control samples, all of the case livers were prepared 
using 1:9 dilutions. 
3.2 Prepare Blood Standards  
Standard solutions #1-7 were prepared using whole sheep blood and working 
stock solutions “A,” “B,” and “C” (Appendix II) which consisted of known opiate 
concentrations. All the whole blood used to make samples was sheep blood acquired 
from Hemostat Laboratories. In addition to standard blood samples #1-7, the calibration 





low-positive and high-positive controls of the blood spiked with known amounts of 
opiates (Table 20 in Appendix III). 
An internal standard, containing the deuterated form of all the opiate compounds 
was added to all the samples including the blood standards and the liver case samples. 
The concentrations of all the components in the internal standard are listed in Appendix 
II. Deuterated samples are structurally identical to the compounds of interest, but have 
stable labeled isotopes; usually deuterium, carbon or nitrogen atoms. These isotopic 
differences allow the internal standard to account for differences which may occur in the 
extraction process and during instrumental analysis as well as provide a measure of 
control in the mass spectroscopy ionization variability and physical properties of the 
compounds of interest. Deuterated internal standards should have the same extraction 
recovery, should co-elute with the compound that’s to be quantified, and should have the 
same chromatographic retention time (AptoChem, 2008).   
3.3 Extraction Procedure  
 Once the blood standard, liver standard, calibrators and case samples were 
prepared, they were ready for the extraction procedure. The samples were mixed with a 
vortex for about thirty seconds, placed in an ultrasonicator bath for ten minutes, and then 
followed by a centrifugation at 3600 revolutions per minute for ten minutes.  The solid 
phase extraction (SPE) tubes were preconditioned using methanol, deionized water, and 
ammonium carbonate according to the procedure in Appendix II. Once the SPE tubes 
were ready, the blood and liver samples were added to the tubes in order to separate the 
compounds of interest. The samples were washed with 0.01 molar ammonium carbonate 





culture tubes. The methanol was evaporated at fifty degrees Celsius and replaced with 
reconstitution solvent. The reconstitution solvent was made up of 95% mobile phase “A” 
(ten millimolar ammonium formate) and 5% of mobile phase “B” (acetonitrile). The 
samples were again, vortexed for twenty seconds, then centrifuged at the same speed for 
about three minutes before placing them in the LC/MS/MS instrument.  
3.4 Quantitating Results 
The specifications of the LC/MS/MS are listed in Appendix II. The 
chromatograph spectrums had the capability to display all the components in the sample, 
or isolate individual components a sample on the spectrum. For the LC/MS/MS 
quantitation conducted in this experiment, two transitions for each component were 
always measured. A transition is the measurement from the analysis of the parent mass of 
the compound during the MS/MS fragmentation, and then monitoring the specific single 
fragment ion. The results are measured in relative intensity vs. retention time.  
3.5 012915 Extraction & Results  
Our first extraction “012915” was performed on all the twenty-one samples, listed 
in Tables 1 & 2 of Appendix III which included the calibrators, the liver dilutions and 
their duplicates. The opioid extraction procedure is listed in Appendix II. Immediately 
following the extraction procedure, all the samples were analyzed using LC/MS/MS. 
Known amounts of opiate drugs were added to the human liver samples 
(displayed in Table 2 of Appendix III), and different concentrations of these drugs were 
present after analysis. Results of this analysis show that 6-monoacetylmorphine (6-
MAM) was not present after analysis (Table 2, Appendix III). It may be possible that 





6-monoaetylmorphine component in vitro such as Moriya discovered with cholinesterase 
activity in the blood while studying other drug components from a cadaver three weeks 
after its storage at room temperature (Moriya, 2005). The results showed the internal 
standard of the 6-MAM to have been metabolized; therefore the 6-MAM component was 
unable to be measured in the liver samples. Observations from using human liver as the 
matrix showed that the more diluted the liver was, the resulting concentration of opiates 
were much lower, and closer in comparison to the concentration values measured from 
the blood analysis. For example, morphine had a higher concentration in the [less dilute] 
1:6 liver (104.95 mcg/L), and had a much lower concentration in [more dilute] 1:30 liver 
dilution (24.05 mcg/L); listed in Table 2, Appendix III.   
Figure 13 is a representation of the 6-MAM in a typical analysis. The top 
chromatogram of Figure 13 is of all the components in the low positive control sample 
from the 012915 extraction. The middle chromatogram is 6-MAM that’s present in the 
sample, and the bottom chromatogram is the deuterated 6-monoacetylmorphine from the 







Figure 13. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the low positive control sample from the 012915 extraction. The top line displays all the 
components in the sample, the middle line displays 6-MAM in the sample, and the 
bottom line represents the 6-MAM internal standard that was added to the sample. The 







Figure 14. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the negative control 1:3 liver sample from the 012915 extraction. The top line displays all 
the components in the sample, the middle line displays 6-MAM in the sample, and the 
bottom line represents the 6-MAM internal standard that was added to the sample. The 
red and blue lines represent two transitions. 
 
Figure 14 is the chromatogram for the negative (1:3) liver sample for the 012915 
extraction. The 6-MAM chromatogram has been singled out for that sample; however its 
normal peaks do not show up in the analysis. The top chromatogram of Figure 14 is of all 
the components in the negative (1:3) liver sample from the 012915 extraction. The 
middle chromatogram displays no measured peaks for 6-MAM sample, and the bottom 





internal standard that was added to the sample for quantitative analysis of the sample, but 
also has no visible reference peaks.    
Finally Figure 15 from the 012915 extraction shows the chromatogram for the 
liver 1:30 dilution sample. The 6-MAM cannot be quantitated because no qualitative 
peaks showed up in the liver sample representing the compound of interest. Also no 
internal standard reference peaks showed up. It’s possible this occurred from some 
interference between 6-MAM and the liver matrix, or the possibility of the presence of 







Figure 15. LC-MS/MS chromatographic peaks for qualitative analysis of 6-MAM in the 
liver 1:30 dilution (#1) sample from the 012915 extraction. The top line is the 
qualititative analysis of components in the sample, the middle line displays 6-MAM in 
the sample, and the bottom line represents the 6-MAM internal standard that was added 
to the sample. The red and blue lines represent two transitions. 
 
Tabulated results for all of the 012915 extraction can be viewed in Tables 1 & 2 
of Appendix III. For the instances where there is no value recorded, it is due to the fact 
that the internal standard was at a level too low to be detected during analysis, and could 
no longer be referenced to calculate the amount of that component in the sample.  





In our second extraction “021215,” we performed extraction and analysis using 
the liver from Case #1. We made 1/3 homogenate with the liver matrix from that case, 
then diluted to have 1/6, 1/9, and 1/15 liver matrix dilutions. The 1/3 dilution was too 
concentrated and outside the range of our upper calibration limit.  
Results from the analysis of Case #1 showed that the 3 liver matrix dilutions did 
work. Values were seen with 1/6, 1/9 and 1/15 dilutions. Morphine was averaged about 
14 times higher in the liver dilutions than the blood, although oxycodone average about 
10 times higher in the liver than in the blood measurements (Table 4, Appendix III). 
Once again, 6-MAM was unable to be analyzed qualitatively or quantitatively for Case 
#1 and Case #1 (duplicate) because there were no peaks present from the compound or 
the internal standard. We proposed the possibility that the liver matrix may be consuming 
the 6-MAM.  
All the dilutions worked well for detecting the analytes in extraction 021215 
especially dilution 1:15; however, we decided to go with the 1:9 dilution for all further 
extractions. The accuracy percentage for morphine was closest to 100% in the 1:9 
dilutions, and we decided this dilution may be appropriate for a wider quantitation range. 
1:9 was also simpler to prepare since we used 1:3 homogenate to prepare the dilutions 
(Tables 3 & 4, Appendix III). 
3.7 021315 Extraction & Results  
Our next step was to see if a cow liver matrix is compatible with internal 
standards and to reanalyze Case #1 in order to compare results to the calf liver 





consisted of calibration standards in whole blood matrix including a negative control of 
whole (sheep) blood, calibration standards in 1:9 dilution calf liver and a negative control 
1:9 calf liver. The extraction procedure was performed, and the samples were run through 
LC MS MS for analysis of the opiates. 
Calf liver results showed more consistent results than the fortified human liver, 
with more of the analytes within 20% accuracy (Tables 6 & 7, Appendix III).  In the 1:9 
calf liver dilutions, all the opiates were within 80-120% accuracy except morphine and 6-
MAM. At 10 mcg/L, morphine was high around (134.5%) accuracy, at 100 mcg/L 
morphine was at (152.5%) accuracy, and at 200 mcg/L for the initial concentration, 
morphine was high (182.5%). In all 3 cases, 6-MAM internal standard was gone; 
therefore the concentration was unable to be measured as shown in Figures 16-18. Figure 
19 also shows that the deuterated form of 6-MAM disappeared in the results for the 
Negative (1:9) calf liver sample which also had internal standard added. All the whole 
[sheep] blood controls performed as expected and 6-MAM was present in the blood 
results as shown in Table 5, Appendix III, as well as in the negative blood control in 
Figure 20.  
Figures 21 and 22 display the quantitative analysis of morphine present in the 
HPC liver (1:9) sample and in the standard 3 sample, and showed morphine to be within 
80-120% accuracy for both of those samples.  
Since the results were satisfactory, we decided to use the calf liver as our 
calibration liver matrix. The calf liver was easier to access, and there was no pre-






Figure 16. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the low positive control (1:9) calf liver sample from the 021315 extraction. The top line is 
the qualitative analysis of components in the LPC 1/9 calf liver sample, the middle line 
displays 6-MAM in the sample, and the bottom line represents the 6-MAM internal 







Figure 17. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the medium positive control (1:9) calf liver sample from the 021315 extraction. The top 
line is the qualitative analysis of components in the MPC 1/9 calf liver sample, the 
middle line displays 6-MAM in the sample, and the bottom line represents the 6-MAM 








Figure 18. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the high positive control (1:9) calf liver sample from the 021315 extraction. The top line 
is all of the components in the HPC 1/9 calf liver sample, the middle line displays 6-
MAM in the sample, and the bottom line represents the 6-MAM internal standard that 







Figure 19. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the negative control (1:9) calf liver sample from the 021315 extraction. The top line is the 
qualitative analysis of components in the sample, the middle line displays 6-MAM in the 
sample, and the bottom line represents the 6-MAM internal standard that was added to 







Figure 20. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the negative sheep blood control sample from the 021315 extraction. The top line is the 
qualitative analysis of components in the sample, the middle line displays 6-MAM in the 
sample, and the bottom line represents the 6-MAM internal standard that was added to 







Figure 21. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine in 
the high positive liver (1:9) control sample from the 021315 extraction. The top line is the 
qualitative analysis of components in the sample, the middle line displays morphine in 
the sample, and the bottom line represents the morphine internal standard that was added 







Figure 22. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine in 
the standard #3 control sample from the 021315 extraction. The top line is the qualitative 
analysis of components in the sample, the middle line displays morphine in the sample, 
and the bottom line represents the morphine internal standard that was added to the 
sample. The red and blue lines represent two transitions. 
 
Table 7 in Appendix III shows the comparison of liver extraction and blood 
extraction analysis for Case #1 and its duplicate from extraction 021315. Morphine 
results were measured at 253.8 mcg/L and 243.9 mcg/L respectively. The toxicology 
results of blood analysis were 18 mcg/L. The morphine measurements in the liver 
calculate to be about 14 times higher in the liver than in the blood which is comparable to 
extraction 021215 results (Table 4, Appendix III); however, the results this procedure 





were very close results (253.8 and 243.9 mcg/L). For Case #1 and its duplicate, 6-MAM 
showed up in the internal standard and was able to be quantitated in the sample (Case #1 
shown in Figure 23), although values were very small at <1 mcg/L. Also there were no 
recorded blood values for the 6-MAM component. Fentanyl results measured to be 
37.440 and 36.315 mcg/L respectively. The toxicology results of blood analysis was 16.6 
mcg/L. Therefore the liver results showed to be 2.22 times higher in the liver than in the 
blood.  Quantitation results for 6-MAM, morphine, morphine-3-glucuronide, morphine-6-







Figure 23. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the Case #1 from the 021315 extraction. The top line is the qualitative analysis of 
components in the sample, the middle line displays 6-MAM present in the sample, and 
the bottom line represents the 6-MAM internal standard that was added to the sample. 







Figure 24. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine in 
the Case #1 from the 021315 extraction. The top line is the qualitative analysis of 
components in the sample, the middle line displays morphine present in the sample, and 
the bottom line represents the morphine internal standard that was added to the sample. 







Figure 25. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine-
3-glucuronide in the Case #1 from the 021315 extraction. The top line is the qualitative 
analysis of components in the sample, the middle line displays morphine-3-glucuronide 
present in the sample, and the bottom line represents the morphine-3-glucuronide internal 







Figure 26. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine-
6-glucuronide in the Case #1 from the 021315 extraction. The top line is the qualitative 
analysis of components in the sample, the middle line displays morphine-6-glucuronide 
present in the sample, and the bottom line represents the morphine-6-glucuronide internal 







Figure 27. LC-MS/MS chromatographic peaks for the qualitative analysis of fentanyl in 
the Case #1 from the 021315 extraction. The top line is the qualitative analysis of 
components in the sample, the middle line displays fentanyl present in the sample, and 
the bottom line represents the fentanyl internal standard that was added to the sample. 







Figure 28. LC-MS/MS chromatographic peaks for the qualitative analysis of norfentanyl 
in the Case #1 from the 021315 extraction. The top line is the qualitative analysis of 
components in the sample, the middle line displays norfentanyl present in the sample, and 
the bottom line represents the norfentanyl internal standard that was added to the sample. 
The red and blue lines represent two transitions. 
 
3.8 6-MAM Conversion Test; Extraction 021916 
Based on the consistent results elevated morphine measurements and missing 6-
MAM concentration, we performed a 6-MAM conversion test using beef liver matrix 
(1/9 dilution) in order to see if morphine was produced after the addition of 6-MAM. No 
internal standard was added which contains all of the deuterated opiate components. 





samples were spiked with known amounts of 6-MAM, 6-MAM d6, morphine and 
morphine d6. Table 2 displays the four samples used in this extraction.  
 
Table 2. Four samples used for the 6-MAM conversion test (extraction 021916) all 
containing 1 gram calf liver 1:9 dilution. 
Sample # Drugs Concentration (mcg/ml) 
1 Negative Control 0 
2 6-MAM 100 
3 6-MAM d6 100 
4 Morphine + Morphine d6 100 + 100 
 
The same extraction and analysis procedure was conducted using these samples 
and controls. LC MS MS results showed that the 6-MAM was possibly converted into 
morphine. The internal standards for morphine and 6-MAM both disappeared, and the 
Figures 29-31 show that the chromatographic peak for morphine was the only component 
present in the samples. Something occurred during analysis to cause the internal standard 
of 6-MAM to disappear. Based on these results we decided to exclude 6-
monoacetlymorphine from the future liver analysis. 6-MAM is very difficult to trace 
from an autopsy case as it is typically the first metabolite to appear in the blood after 
heroin has been administered into the human body, but  then quickly converts to 







Figure 29. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM in 
the liver 1:9 dilution from the 021915 extraction. The top line is the qualitative analysis 
of components in the sample, the middle line displays 6-MAM in the sample, and the 
bottom line represents the 6-MAM internal standard that was added to the sample. The 







Figure 30. LC-MS/MS chromatographic peaks for the qualitative analysis of 6-MAM 
internal standard (6-MAM d6) in the liver 1:9 dilution from the 021915 extraction. The 
top line is the qualitative analysis of components in the sample, the middle line displays 
6-MAM d6 in the sample, and the bottom line represents the 6-MAM d6 internal standard 







Figure 31. LC-MS/MS chromatographic peaks for the qualitative analysis of morphine in 
the liver 1:9 dilution from the 021915 extraction. The top line is the qualitative analysis 
of components in the sample, the middle line displays morphine in the sample, and the 
bottom line represents the morphine internal standard that was added to the sample. The 
red and blue lines represent two transitions. 
 
3.9 030515 Extraction & Results   
Once the procedure was established and proved practical, we created new 
working stock solutions for our calibrators without 6-MAM to prevent any possible 
disruptions in 6-MAM and morphine measurements (Tables 21 & 22, Appendix III). 
Once new calibrators were made, we proceeded to analyze sixty-four (64) cases through 





standard to all of the samples. The internal standard contained the deuterated form of all 
the analytes, including 6-MAM (Internal standards section of Appendix II).  
Results from this extraction of Case #1-10 can be viewed in Table 9, Appendix 
III. Morphine had concentrations for the blood and liver analysis in Case #1, #3, #4, and 
#9. In Case #1, alcohol and drugs other than opiates were present at time of analysis, and 
morphine was about 13 times higher in the liver than the blood. Case #3 showed the liver 
to be 1.4 times more concentrated in the liver than in the blood, and in Case #4 the liver 
was 2.9 times more concentrated than the blood. Cases #9 & #10 were decomposition 
cases, where blood was not available for sampling due to the extreme putrefaction of the 
organs. The specimen collected for the initial quantitation analysis was fluid which was 
collected from the right side of body cavity, termed “decomposition fluid” (Private 
conversation with Dr. Maloney, Associate Chief Medical Examiner, Erie County Medical 
Examiner’s Office, March 30, 2016). In case #9, analysis showed that decomposition 
fluid was five times more concentrated with morphine than the liver. For Case #9 
oxycodone and morphine-3-glucuronide resulted with higher concentration in the 
decomposition fluid than in the liver, this may have occurred due to the time that this 
individual’s heart stopped pumping blood which allowed the blood to retain all the drugs 
which eventually turned into “decomposition fluid” and halted any additional drugs from 
traveling to the liver for further metabolic processing.  
For many of the analytes that did not have a quantitative value from the blood 
analysis, there was a value for the liver analysis. Morphine-6-glucuronide in Case #2 was 
measured at 78.278 mcg/L in the liver; however, there was no value in the blood analysis. 





concentration for morphine-3-glucuronide present as well. Morphine-3-glucuronide was 
about 1.5 to 3 times more concentrated in the liver than in the blood for cases #1, #3, #4 
and #5. For case #1 and #3, morphine-6-glucuronide was analyzed to be 3 and 5 times 
more concentrated in the liver than in the blood, respectively.  Case #4 was 24 times 
more concentrated with morphine-6-glucuronide in the liver than in the blood, and case 
#5 only had a concentration in the liver and not in the blood.  
Codeine was another opiate that was present with a concentration in the liver for 
all the cases in this extraction, but only for cases #3 and #4 was there a concentration in 
the blood for comparison. In case #3 the codeine concentration was about the same in the 
liver and blood, and case #4 the liver was twice as concentrated as the blood. 
Oxycodone had concentrations in the blood and the liver for Cases #2, #6, #7, and 
#8. These four cases were all females between 120 and 185 pounds that may have 
involved acute ingestion of oxycodone and in two cases possibly methadone. Case #2 had 
about twice the concentration of codeine in the liver than in the blood, Case #6 and #7 
had similar concentrations in the liver and the blood, and case #8 had about 5 times the 
concentration of codeine in the liver than in the blood. Drugs other than opiates were 
present in all of the cases except Case #6, and a wide variety of drugs were found to be 
present for Case #8. 
Case #10 was another decomposition case which resulted in 7900 mcg/L present 
in the decomposition fluid, and zero concentration in the liver. Oxymorphone, 
hydrocodone and hydromorphone were present in case #10 and those analytes all had a 





codeine was present in the liver quantitation and no codeine concentration was measured 
from the blood analysis (table 9 Appendix III). The case history suggests that a 
prescription bottle of oxycodone was ingested by the individual at time of death, and the 
death was ruled as an acute oxycodone and hydrocodone intoxication in Appendix IV.  
Oxymorphone, hydromorphone, hydrocodone, and oxycodone can be prepared 
from solutions of codeine, so it’s possible that codeine may have been present in analysis 
from the manufacturing process of these drugs if they were ingested (German Patent, 
1936). Oxymorphone, oxycodone, codeine, hydrocodone and hydromorphone have all 
been subject to post mortem distribution (PMR) in past studies (Baselt, 2011). PMR may 
have altered the true concentration measurements of these drugs since this individual was 
considered decomposed before conducting the autopsy; allowing for a maximum time for 
post mortem redistribution of drugs in this individual’s organs, and tissues, including the 
stomach, which may be a factor as to why a significant amount of oxycodone was 
measured in the blood (Moriya, 2005; Pélissier-Alicot, 2003).  
 Stomach contents are collected at the Erie County Medical Examiner’s Office 
when there is a suspected intentional overdose case, and usually for the cases when the 
individual is an infant. When sampled, all of the gastric contents must be collected; 
however, the contents are only analyzed if the blood is not a satisfactory representative of 
the drug components present in the individual at the time of death. Since all the cases in 
this study, including case #10 had a significant concentration of drug components from 
the blood and decomposition fluid analyses, the stomach contents were not analyzed 
(Private conversation with Dr. Maloney, Associate Chief Medical Examiner, Erie County 





As previously stated; oxycodone and hydrocodone are metabolized in the liver by 
CYP2D6 into their major metabolites respectively, oxymorphone and hydromorphone 
(Purdue Pharma LP, 2016; Vuilleumier, 2012). In case #10, although there was a high 
concentration of oxycodone in the blood and none present in the liver, 281.25 ųg/L 
oxymorphone was still present from the liver analysis. In comparison, 6 ųg/L 
hydrocodone, and 10 ųg/L of the metabolite hydromorphone were measured in the blood 
while 91.8 ųg/L and 46.49 ųg/L were measured in the liver respectively; the increased 
values most likely due to the hepatic metabolism characteristics of these drugs.   
The highest measurement where there were values in both the liver and the blood 
in this extraction was for oxymorphone in Case #2.  In this case the oxymorphone 
concentration was about 16 times higher in the liver than in the blood. 
Buprenorphine had a detectable level in the liver for each case in this extraction. 
Case #10 had the highest concentration for buprenorphine which was measured at 
343.512 mcg/L. Even at that high of a concentration there was no detection of 
buprenorphine measured from the blood analysis.  
3.10 032015 Extraction & Results 
Results from this extraction of Case #11-20 can be viewed in Table 11, Appendix 
III. Morphine was analyzed in Case #13, #19, and #20. All the cases had about 3-5 times 
higher concentration of morphine in the liver than the blood. Case #13’s height and 
weight were previously mentioned at 65 inches, 124 pounds, while Case #19 was at 65.5 
inches, 226 pounds, and Case #20 was 66.5 inches, 283 pounds. #19 and 20 had a known 





body at time of initial analysis, and Case #13 and #19 had alcohol present in their 
toxicology screening analysis.   
Case # 11, #17, and # 19 all had 30 mcg/L of hydrocodone from the blood 
analysis. For Case #11, hydrocodone measurements were about nine times higher in the 
liver than the blood. Case # 17 & # 19, measurements for hydrocodone were respectively, 
about five and three times higher in the liver than the blood. Alcohol was present in cases 
#11 & #19, and all three cases had a history of drug abuse, and other drugs present at the 
time of death. The only noted difference in the three cases is that Case #11 had CPR 
initiated; the decedent was intubated and given epinephrine, naloxone, calcium and 
sodium bicarbonate. It may be possible that the liver was functioning longer in Case #11 
than the other overdose cases as an explanation for the higher concentration in the liver 
(about nine times higher than the blood) than the other two cases.  
In this extraction, hydromorphone was measured in the liver analysis only for 
cases #11-14, and #17-20. Only case #12 had a concentration in the blood and liver, and 
the blood was about five times more concentrated with hydromorphone than the liver. 
Case #12 was a 56 year old male at 61 inches, 83 pounds with a known history of drug 
abuse and only opiates present in the body at time of analysis. In the case history it was 
stated that this individual never saw a doctor. Noting the case history, and the low weight 
of this individual, to explain the low concentration of hydromorphone in the liver, it may 
be possible the liver in this case#12 was not functioning as that of a healthy individual.  
Fentanyl was compared between liver and blood analysis in Table 11, Appendix 





the liver analysis; in contrast, Case #18 was almost 27 times higher in the liver than the 
blood analysis. Both cases had only opiates present from the initial drug screening, but 
only Case #12 had a known history of drug abuse. As previously mentioned, Case #12 
was 61 inches and 83 pounds, while Case #18 was almost twice that size at 73 inches, 
173 pounds. Case #13 was 65 inches, 124 pounds, alcohol was present in the body and 
the fentanyl measured to be about 10 times more concentrated in the liver than the blood. 
Cases #15 and #16 both had other drugs present at the time of drug screening, and had 
about three times more fentanyl concentration in the liver than the blood. Case #15 was 
72.5 inches, 191 pounds and Case #16 was 71 inches, 236 pounds with a known history 
of past drug abuse. Using height and weight measurements, one can calculate the mean 
mass ratio which is important in pharmacological investigations of determining 
appropriate dosage levels when prescribing drugs (Pharmacorama, 2006). Such 
calculations were performed to determine the dosage levels in select individuals at the 
time of death. Calculations for two cases were performed on two cases which are 
documented in Appendix V.  
Norfentanyl was about the same liver: blood concentration ratio as fentanyl in 
case #12 and Case #16. In Case #12, fentanyl concentration was 1.3 times higher in blood 
than liver, norfentanyl concentration was about 1.5 times higher in blood than liver. In 
case #16, fentanyl concentration was 3.1 times higher in liver than blood, and norfentanyl 
concentration was about 3.7 times higher in liver than blood. in case #13, norfentanyl was 
half as concentrated as fentanyl in the liver than blood (fentanyl 10 times more 
concentrated in liver than blood, norfentanyl four times more concentrated in liver than 





and finally Case #18 only had norfentanyl concentration detected in the liver analysis 
even though fentanyl had a measureable concentration in the blood and the liver analysis.  
Buprenorphine and norbuprenorphine had measurements in the liver analysis for 
all the cases in this extraction (Case #11-20). The measured concentration for 
norbuprenorphine in the liver was higher than buprenorphine in each case. 
3.11 032815 Extraction & Results 
All the individuals in this set of cases were between 148 and 284 pounds. Results 
from this extraction of Case #21-29 can be viewed in Table 13, Appendix III. Case #24 
had the highest concentration of morphine out of the study at almost 4000 (3982.5) 
mcg/L in the liver, about 12 times the concentration of the blood. The other Cases #21, 
23, 26, 28 and 29 had the morphine concentration in the liver around 1.5 to 6 times the 
concentration from the blood. Out of these five cases, all but case #26 had drugs other 
than opiates present at the time of screening.  
Morphine-3-glucuronide was also present in the liver analysis for all the cases in 
this extraction set. Case #26, and #29 the concentration was in the blood and liver 
analysis and about 3 and 1.4 times higher concentration in the liver than in the blood, 
respectively. Case #24 and Case #26 had morphine-6-glucuronide present in the blood 
and liver analysis and was about four and five times higher in the liver than in the blood, 
respectively. 
Codeine was present in the liver analysis for all the cases #21-29 for this 
extraction. Only case #21 and #26 had a concentration for codeine in the blood and liver. 





Oxycodone was only present in Case 24 of this extraction set, and was found to be 
almost three times more concentrated in the liver than in the blood.  
In this set of case extractions, the lower the concentration of fentanyl present in 
the liver, the higher concentration difference between the liver and the blood. For Case # 
22, 23, 26, and 29 the blood concentration was between 2.7-14.8 mcg/L and the liver 
concentration about 10-23 times higher in the liver. Case # 27 and 28 had fentanyl 
concentration of 37.8 and 35.8 mcg/L respectively in the blood analysis, and was only 
four to seven times more concentrated in the liver.  
Norfentanyl had a concentration in the blood and liver in Case # 23, 26, 27 and 
28. In all cases, the concentration was between 3.6 and 7.6 times higher in the liver than 
in the blood.  
All the cases in this extraction (case #21-29) except Case #27 had 
norbuprenorphine present in the liver analysis. Buprenorphine was only present in the 
liver analysis for Case #26 and Case #28. Case #28 had a concentration for both 
buprenorphine and norbuprenorphine in the liver and blood; norbuprenorphine was about 
eight times higher concentration in the liver than blood and buprenorphine was about five 
times higher in the liver than blood.  
3.12 041815 Extraction & Results 
Four cases in this extraction set were positive for morphine in the blood and liver 
analysis. Case #31, #32, #34 and #38 had morphine concentration 13-40 mcg/L in the 
blood. Analysis of the liver showed morphine concentration to be about two to four times 





in the blood. This individual was 330 pounds with a known history of drug abuse, only 
opiates present at time of screening, and the liver analysis showed the morphine 
concentrations was 3.76 times higher in the liver than the blood.  
Cases #32-38 had had a concentration of fentanyl in both the blood and liver. All 
but case #37 had a known history of drug abuse. Case #32 was the only female in this 
group of extractions, as well as the oldest individual; 47 years old at 176 pounds. 
Fentanyl was at five times higher concentration in the liver than the blood. The other 
cases #33-38 were males between the ages of 29 and 36 years old. Case #34 had the 
lowest concentration difference of fentanyl; about 8 times higher in the liver than the 
blood, while Case #37 had the biggest difference; close to 33 times higher in the liver 
than the blood. Case #37 had drugs other than opiates present in the body at time of 
screening, was 69.6 inches, and 222 pounds.  
Norfentanyl, the metabolite of fentanyl was present in all the cases that had 
fentanyl for this extraction and at a much lesser concentration difference for all the cases 
except case #36. All the cases with norfentanyl were around half to a quarter of the 
concentration difference in the liver and blood for fentanyl, but Case #36 was about 11 
times higher in the liver than the blood for fentanyl and norfentanyl (Table 15, Appendix 
III). Case #36 had the highest measured concentration of fentanyl in the liver out of all 
the cases in this extraction set at 410.4 mcg/L; also a known history of drug abuse and 
only opiates in the body at time of screening. As previously stated, fentanyl is primarily 
metabolized in the liver where it becomes norfentanyl. According to Mayes, once 
administered in the body, the distribution time for fentanyl is about six minutes, with a 60 





excreted as norfentanyl and about 10 percent is excreted as fentanyl through the urine and 
bile (Mayes, 2006).   
In all the cases where buprenorphine and norbuprenorphine were measured for 
this extraction, had higher concentration for norbuprenorphine each time. In case #36, 
norbuprenorphine (11.97 mcg/L) was nearly eight times higher buprenorphine (1.566 
mcg/L) in the liver concentration shown in Table 15, Appendix III.  
3.13 060915 Extraction & Results 
Results from this extraction of Case #39-52 can be viewed in Table 17, Appendix 
II. Case #40, #40, #42, #45, #46, #47, #51, #52 had morphine measurements in the liver 
and the blood. Case # 48 was the only case in the entire study that had a blood 
measurement that had no concentration measured in the liver. A concentration of 3 mcg/L 
of morphine was measured in the blood and no morphine was detected in the liver 
analysis. Morphine-3-glucuronide had a concentration in the blood and liver for this case, 
but the liver had lower levels than the blood (16 mcg/L in Blood, 0.6174 mcg/L in liver). 
Case #48 had a known history of drug abuse and drugs other than opiates were present in 
the body at time of analysis. 
 After a drug is administered orally, it gets absorbed by the digestive system and 
is subjected to hepatic metabolism usually carried to the liver through the portal vein 
before it reaches systemic circulation (Rowland, 1972). First pass metabolism greatly 
reduces the bioavailability, or initial dose of the unchanged the drug due to incomplete 





intravenously, its bioavailability is 100% because it avoids first-pass metabolism and 
reaches systemic circulation immediately through the bloodstream (Griffin, 2009).  
Case #48 had a medical history of Hepatitis C, a history of heroin use, and 
evidence of syringes present at the scene of the death. Evidence of syringes found at the 
scene may suggest the decedent administered drugs intravenously, in which case the 
bioavailability of drugs in the decedent would be 100%, and would have reached 
systemic circulation before passing through the liver for detoxification. Based on 
evidence for Case #48 and knowledge drug metabolism; if the decedent administered 
these opiate drugs intravenously, it is possible the death was rapid and there was 
insufficient time for these drug components to be metabolized in the liver. These events 
may help explain why a morphine concentration was measured in blood and not liver.  
Hepatitis C may cause inflammation of the liver, death of liver cells, scarring and 
cirrhosis of live tissue. It is also worth noting for this case, if the liver had failed to filter 
toxins due to the progression of Hepatitis C in this decedent, the toxins would build up in 
the bloodstream rather than the liver (Pietrangelo, 2016).  
Throughout this study, for most of the cases, the liver was measured to have a 
higher concentration of the drugs than were present in the blood. For the other cases in 
this extraction set that compared morphine in the blood and liver, the concentration was 
between one and four times higher in the liver than the blood, except case #52 where the 
concentration of morphine was about eight times higher in the liver than blood.  
For the cases in this extraction; morphine-3-glucuronide was present in the liver 





concentration measured in the blood and liver for morphine-3-glucuronide, the 
concentration in the liver was between one and three times higher in the liver than in the 
blood with the exception of Case #48 and Case #51. In Case #48, morphine-3-
glucuronide was higher in the blood than the liver, and Case #51 the concentration for 
morphine-3-glucuronide was about ten times higher in the liver than in the blood. 
Morphine-3-glucuronide and morphine-6-glucuronide are metabolites of 
morphine. Morphine-3-glucuronide was mostly present whenever morphine was 
throughout this study; however, morphine-6-glucuronide was present less often than 
morphine-3-glucuronide. In this extraction morphine-6-glucuronide was present in half 
the cases where morphine was present in the blood measurements (Case #40, #46, #47, 
#51). In these cases the concentration of morphine-6-glucuronide was between one and a 
half, and three times higher in the liver than the blood, except Case #47 where it was 
about 10 times higher in the liver than the blood. Case #47 was a seventeen year old 
female with a known history of drug abuse and drugs other than opiates present in the 
body at time of screening. These characteristics may have affected the increase 
concentration in the liver compared to the blood.  
Hydrocodone was analyzed in Case #40, #43, and #44 in this extraction and was 
found to be one, three, and four times higher concentration in the liver than the blood 
respectively.  
Fentanyl concentration was compared in the blood and liver in case #40-44, #46-
50, and #52. All these cases had a known history of drug abuse and all but case #41 had 





the lowest concentration difference in the liver and blood about six and eight times higher 
in the liver than the blood. All the other cases were analyzed to have fentanyl around 
eleven to twenty three times higher in the liver than in the blood. There were no special 
correlations found to explain the extreme difference between the concentration 
differences measured in the liver and the blood.  
Norfentanyl had a concentration present in the liver and blood for each of the 
cases where fentanyl was present in the liver and blood. Norfentanyl was also present in 
Case #39 at a higher concentration of nearly six times in the blood than in the liver. For 
Case #39, fentanyl was not measured in the blood and only present in the liver analysis 
(38.43 mcg/L). This case (#39) had a known history of drug abuse and like many of the 
other cases had other non-opiate drugs present in the body at time of screening. All the 
other cases where norfentanyl was analyzed in the blood and liver, there was at least 4 to 
11 times higher concentration of norfentanyl in the liver than in the blood. 
Buprenorphine and norbuprenorphine had measurements in the liver analysis for 
all the cases in this extraction (Case #39-52). The measured concentration for 
norbuprenorphine was higher than buprenorphine every time. Buprenorphine is 
metabolized in the liver by cytochrome P450 Enzyme CYP3A4 where it’s converted into 
norbuprenorphine. A study performed by McMillin consisted of 1,946 urine samples in 
effort to display patterns of buprenorphine and its metabolites. The study showed 97.9% 
of the samples tested positive for norbuprenorphine, and 45.5% of the samples tested 
positive for buprenorphine (McMillin, 2012). These results support the idea that 





addition to supporting reasoning for the results of Cases #39-52 where the concentration 
of norbuprenorphine was higher than buprenorphine in the liver.  
3.14 061015 Extraction & Results 
Results from this final extraction of Cases #53-64 can be viewed in Table 19, 
Appendix II. Cases #53, #60, and #62-64 had morphine concentrations in the liver and 
blood analysis. All were between one and five times higher in the liver than in the blood 
except Case #60 which had a little over half as much morphine in the liver than in the 
blood (4 mcg/L in the blood, 2.421 mcg/L in the liver), and a similar concentration 
morphine-3-glucuronide (7 mcg/L in blood, 4.473 mcg/L in liver). Case #60 was a 22 
year old male with a known history of drug abuse and only opiates in the body at time of 
analysis. According to the blood analysis, fentanyl and norfentanyl were the only other 
drugs present in this individual at time of analysis. Case #60 was 65 inches, 136 pounds, 
based on all of these known characteristics, it remains unknown how the morphine 
concentration and morphine-3-glucuronide concentration would be lower in the liver than 
in the blood. 
Morphine-3-glucuronide was present in the liver and blood samples in all cases 
where morphine was present. Concentrations varied between liver and blood. Each time 
morphine-6-glucuronide was present in this extraction set; this metabolite was more 
concentrated in the liver than in the blood analysis compared to blood/liver concentration 
comparison of morphine-3-glucuronide. Case #62 had a morphine concentration twice as 
high in the liver than in the blood, but the metabolite morphine-3-glucuronide was 1.5 
times higher in the blood than in the liver. For Case #62 the morphine-6-glucuronide 





analysis (160 and 166.5 mcg/L, respectively). Case #53 measured morphine-3-
glucuronide to be close to four times in the liver than the blood, and morphine-6-
glucuronide had a concentration in the liver, but not in the blood. Case #63 was measured 
to have 2.5 times the concentration of morphine-3-glucuronide in the liver than in the 
blood, and morphine-6-glucuronide was about 16 times higher in the liver than the blood. 
In Case #64, morphine-3-glucuronide was measured to be about ten times more 
concentrated in the liver than in the blood, and morphine-6-glucuronide was 29 times 
more concentrated in the liver than in the blood.  
In this set of Cases #53-64, codeine had a concentration measurement in the liver 
for each; however, the blood analysis only detected codeine in three of these cases: #62, 
#63, and #64. For these three cases, the concentration of codeine was between one and 
three times more concentrated in the liver than in the blood.  
Hydrocodone was only detected in Case # 59 for this extraction, and was found to 
be 3.6 times more concentrated in the liver than in the blood.  
A concentration for fentanyl was detected in the liver analysis for all the cases in 
this set, and for the blood analysis, all but Case #62 had detected a fentanyl 
concentration.  When comparable, the concentration of fentanyl was between two and 
fourteen times higher in the liver than in the blood.  
Norfentanyl had a concentration present in both the liver and the blood for most 
of the cases (#53-58, #60, and #61). For all of those cases except #58 and #61, the 
amount of norfentanyl higher in the liver than the blood was half the times higher in liver 





concentrated in the liver than the blood, and norfentanyl was about half, or five times 
more concentrated in the liver than in the blood. For the exceptions case #58 and case 
#61, the fentanyl was the same amount higher in the liver than in the blood as norfentanyl 
was. Case #58 was about five times more concentrated in the liver than the blood for 
fentanyl and norfentanyl, Case #61 was about three times more concentrated in the liver 
than in the blood for fentanyl and norfentanyl. Case #59, #62, #63, and #64 norfentanyl 
was only detected in the liver. It is likely that norfentanyl was at concentrations too low 
to be detected in the blood.  
Norbuprenorphine had measurements in the liver analysis for all the cases in this 
extraction (Case #53-64). When buprenorphine had a concentration detected in the liver, 
the measured concentration for norbuprenorphine was higher than buprenorphine in all 









Results from the six opiate extractions (030515, 032015, 032815, 041815, 
060915, and 061015) had no interference between the analytes and the liver matrices 
from the quantitative data. All the samples were spiked with an internal standard of the 
deuterated compounds of interest in order to detect any interference between the drug 
components and blood and liver matrix. Also, the internal standard is necessary in order 
to act as a measure of control during the extraction process, instrumental analysis and 
quantitation procedure.  
The calibration samples included one sample of whole blood used as a negative 
control, seven standard solutions, pre-prepared low-positive and high-positive controls of 
the blood, and also high, medium and low (1:9) liver dilution controls, all which were 
spiked with known amounts of opiates and internal standard in order to monitor 
performance and interferences during analysis. The high and low blood controls were 
pre-prepared and had lot numbers recorded in case systemic errors occurred. The 
extraction columns also had lot numbers recorded in the event of any troubleshooting that 
may have occurred during the extraction procedure. 
The tables in Appendix III where blood analysis is compared to liver analysis, 
many of the extraction results showed more analytes present in the liver than in the blood. 
In many instances there were values for opiates in the liver but not in the blood. Many 
times there were values for opiates in the liver analysis, but not the blood analysis. It is 





detection, but just above the limit of detection in the 1:9 liver analyses. Despite these 
occurrences, there were no observed, predictable quantitative correlations between the 
opiates found in the liver compared to the blood analyses. 
Figures 32 & 33 and Tables 3 & 4 show the percentage comparisons of drugs 
present in all 64 cases studied after blood analysis and liver analysis. Fentanyl was 
detected in about sixty-six (65.63) percent of total cases from quantitation of the opiates 
in the blood analysis. Results of the liver analysis showed norbuprenorphine to appear in 
close to ninety-five (95.31) percent of all the sixty-four cases analyzed, and fentanyl 
appeared in about eighty-eight (87.50) percent of the cases.  
Figures 34-45 and Tables 5-16 display each of the 12 measured opiates and the 
cases in which they were present. The concentration of these opiates is charted when 
present in the liver and in the blood. Case #24 had the highest amount of morphine 
detected from the liver analysis at 3982.5 mcg/L when compared to the blood analysis. 
The concentration in the blood analysis for that case was 320 mcg/L. Case #19 had the 
highest amount of morphine measured from the blood quantitation, at 460 mcg/L, with 
only 1386 mcg/L measured from the liver analysis. Hydromorphone was not frequently 
found detected in the cases for this project only showing up in the blood and liver 
analysis for Cases #10, #12 and #25. Codeine showed up in the analyses for ten of the 
cases with the highest concentration at 40.41 mcg/L in the liver and 18 mcg/L in the 
blood for Case #19. The liver concentration for codeine was about two times higher than 
the blood concentration in that case. Case #25 had the highest concentration for 
hydrocodone in both the blood and the liver at 845.1 mcg/L and 420 mcg/L, respectively. 





#25. Oxymorphone was analyzed in five cases out of the total cases analyzed in the 
project. The highest concentration difference of this opiate was measured in Case #2 
where oxmorphone was over sixteen times higher concentration in the liver than in the 
blood. Oxymorphone was measured at 83.205 mcg/L in the liver and at 5 mcg/L in the 
blood for Case #2. Case #2 had the highest amount of oxycodone detected from the liver 
analysis at 1318.5 mcg/L. The liver concentration was almost two times the concentration 
of the blood analysis for that case which was measured at 730 mcg/L. Morphine-3-
glucuronide was measured in twenty-four cases. The highest concentration in the liver 
was measured at 1053 mcg/L, about ten times higher than the blood analysis 
measurement for Case #51. Morphine-6-glucuronide was measured in fourteen cases with 
the highest concentration from the liver analysis at 1633.5 mcg/L; about five times higher 
than the blood concentration measurement in Case #24. Case #64 had a morphine-6-
glucuronide concentration at 377.1 mcg/L from the liver analysis, and at 13 mcg/L from 
the blood analysis, a concentration twenty-nine times higher in the liver than in the blood. 
Norfentanyl had a concentration measured in the blood for 57.81% of the cases, and a 
concentration in the liver for 87.50% of the cases. Case #55 had the highest concentration 
of norfentanyl which was measured at 97.65 mcg/L in the liver, while the concentration 
was 35.4 mcg/L in the blood. Fentanyl had a measurement in the blood for 65.63% of the 
cases analyzed, and a measurement in the liver for 87.50% of the cases. The highest 
concentrations for fentanyl were measured in the liver, measuring around 530.1-582.3 
mcg/L, while the highest concentration measured in the blood was 112.2 mcg/L. 
Norbuprenorphine was measured in the liver for 95.31% of the cases, however, only six 





concentrations. Case #55 had the highest norbuprenorphine concentration measured from 
the liver analysis was 50.895 mcg/L while the measurement in the blood was 6.6 mcg/L. 
Buprenorphine concentrations showed up in 75.00% of the cases from the liver analysis, 
and 9.38% of the cases from blood analysis. When both values were compared, Case #55 
again, had the highest measurement for buprenorphine in the liver at 34.65 mcg/L, and 






Figure 32. Percent of opiates present in 64 suspected overdose cases that were analyzed 
with blood samples. 
 
Table 3. Tabulated values from Figure 32. 
Drugs 
Number of cases 
where drug was 
present in Blood 
Analysis 
Percent of time drug was 
found in the 64 cases 
Hydromorphone 3 4.69% 
Oxymorphone 5 7.81% 
Norbuprenorphine 6 9.38% 
Buprenorphine 6 9.38% 
Hydrocodone 8 12.50% 
Oxycodone 8 12.50% 
Codeine 10 15.63% 
Morphine-6-Glucuronide 14 21.88% 
Morphine-3-Glucuronide 24 37.50% 
Morphine 30 46.88% 
Norfentanyl 37 57.81% 







Figure 33. Percent incidence of drugs present in 64 suspected overdose cases measured 
from liver analysis. 
 
Table 4. Tabulated values from Figure 33. 
Drugs 
Number of cases where 
drug was present in Liver 
Analysis 
Percent of time drug was 
found in the 64 cases 
Oxycodone 9 14.06% 
Oxymorphone 14 21.88% 
Hydrocodone 15 23.44% 
Hydromorphone 18 28.13% 
Morphine 33 51.56% 
Morphine-6-Glucuronide 39 60.94% 
Codeine 47 73.44% 
Morphine-3-Glucuronide  48 75.00% 
Buprenorphine 48 75.00% 
Norfentanyl 56 87.50% 
Fentanyl 56 87.50% 













Table 5. Tabulated values comparing the concentration of morphine in the blood and 
liver. 









Times higher in 
liver than blood 
1 23 Male 67 139 18 237.15 13.175 
3 24 Male 66 146 100 143.55 1.436 
4 21 Female 62 147 180 515.25 2.863 
13 28 Female 65 124 70 242.1 3.459 
19 26 Male 65.5 226 460 1386 3.013 
20 17 Male 66.5 283 200 1048.5 5.243 
21 34 Male 77.5 228 230 396.45 1.724 
23 28 Male 71 191 18 113.85 6.325 
24 45 Female 64 159 320 3982.5 12.445 
26 45 Male 73 231 260 815.85 3.138 
28 42 Female 62 138 2 8.577 4.289 
29 22 Male 75.5 284 3 4.374 1.458 
31 50 Male 70 221 30 87.435 2.915 
32 47 Female 62.5 176 20 42.66 2.133 
34 32 Male 71.5 162 13 42.84 3.295 
38 32 Male 69.5 330 40 150.3 3.758 
40 35 Female 63 181 12 25.83 2.153 
42 44 Male 72 217 5 3.564 0.713 
45 48 Female 63 175 13 21.6 1.662 
46 26 Female 64 116 10 38.43 3.843 
47 17 Female 62 146 210 475.65 2.265 
48 34 Male 72 168 3 0 0 
51 31 Male 70.5 259 190 784.8 4.131 
52 32 Male 74 163 19 152.55 8.029 
53 36 Male 73 284 7 37.125 5.304 
60 22 Male 65 136 4 2.421 0.605 
62 28 Female 62 177 90 186.3 2.070 
63 32 Male 68.5 170 150 450.9 3.006 
64 40 Female 64 159 280 378.9 1.353 
 
Table 5a. Tabulated values comparing the concentration of morphine analyzed in the 
decomposition fluid and liver. 










Times Higher in 
Liver than Blood 







Figure 35. Comparison of the hydromorphone concentration in the liver and the blood. 
 
Table 6. Tabulated values comparing the concentration of hydromorphone analyzed in 
the blood and liver. 









Times Higher in 
Liver than Blood 
12 56 Male 61 83 70 12.735 0.182 
25 52 Male 72 148 5 8.307 1.661 
 
Table 6a. Tabulated values comparing the concentration of hydromorphone analyzed in 
the decomposition fluid and liver. 
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Figure 36. Comparison of the codeine concentration in the liver and the blood.  
 
Table 7. Tabulated values comparing the concentration of codeine analyzed in the blood 
and liver. 









Times Higher in 
Liver than Blood 
3 24 Male 66 146 6 5.9895 0.998 
4 21 Female 62 147 11 20.97 1.906 
19 26 Male 65.5 226 18 40.41 2.245 
21 34 Male 77.5 228 9 17.01 1.890 
26 45 Male 73 231 6 12.69 2.115 
38 32 Male 69.5 330 2 3.033 1.517 
51 31 Male 70.5 259 12 16.56 1.380 
62 28 Female 62 177 3 4.815 1.605 
63 32 Male 68.5 170 7 11.385 1.626 







Figure 37. Comparison of the hydrocodone concentration in the liver and the blood. 
 
Table 8. Tabulated values comparing the concentration of hydrocodone analyzed in the 
blood and liver. 









Times Higher in 
Liver than Blood 
11 75 Female 64 113 30 277.65 9.255 
19 26 Male 65.5 226 30 94.5 3.150 
25 52 Male 72 148 420 845.1 2.012 
30 44 Female 62.5 148 230 426.15 1.853 
40 35 Female 63 181 4 3.6135 0.903 
43 33 Male 69 205 70 177.3 2.533 
44 49 Male 72.5 212 17 66.51 3.912 
59 37 Male 72 236 60 218.25 3.638 
 
Table 8a. Tabulated values comparing the concentration of hydrocodone analyzed in the 
decomposition fluid and liver. 
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Liver than Blood 






Figure 38. Comparison of the oxymorphone concentration in the liver and the blood. 
 
Table 9. Tabulated values comparing the concentration of oxymorphone analyzed in the 
blood and liver. 









Times Higher in 
Liver than Blood 
2 36 Female 64 140 5 83.205 16.641 
14 45 Male 71 237 20 105.75 5.288 
15 24 Male 72.5 191 30 67.635 2.255 
47 17 Female 62 146 4 2.088 0.522 
 
Table 9a. Tabulated values comparing the concentration of oxymorphone analyzed in the 
decomposition fluid and liver. 
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Figure 39. Comparison of the oxycodone concentration in the liver and the blood. 
 
Table 10. Tabulated values comparing the concentration of oxycodone analyzed in the 
blood and liver. 









Times Higher in 
Liver than Blood 
2 36 Female 64 140 730 1318.5 1.806 
6 46 Female 67 122 130 153 1.177 
7 33 Female 59.5 183 420 527.4 1.256 
8 53 Female 64 123 220 1003.5 4.561 
24 45 Female 64 159 10 27.135 2.714 
47 17 Female 62 146 90 101.25 1.125 
 
Table 10a. Tabulated values comparing the concentration of oxycodone analyzed in the 
decomposition fluid and liver. 










Times Higher in 
Liver than Blood 
9 52 Female 65.5 240 140 8.289 0.059 













Table 11. Tabulated values comparing the concentration of morphine-3-glucuronide 
analyzed in the blood and liver. 









Times Higher in 
Liver than Blood 
1 23 Male 67 139 190 284.4 1.497 
3 24 Male 66 146 250 557.1 2.228 
4 21 Female 62 147 330 958.5 2.905 
5 0 Female 10 1 12 37.98 3.165 
13 28 Female 65 124 120 241.2 2.010 
26 45 Male 73 231 180 583.2 3.240 
29 22 Male 75.5 284 20 28.665 1.433 
31 50 Male 70 221 130 85.59 0.658 
32 47 Female 62.5 176 370 119.25 0.322 
34 32 Male 71.5 162 18 29.925 1.663 
38 32 Male 69.5 330 290 386.55 1.333 
40 35 Female 63 181 40 43.65 1.091 
42 44 Male 72 217 17 14.04 0.826 
46 26 Female 64 116 30 17.1 0.570 
47 17 Female 62 146 330 990 3.000 
48 34 Male 72 168 16 0.6174 0.039 
51 31 Male 70.5 259 >100 1053 >10.636 
52 32 Male 74 163 80 103.5 1.294 
53 36 Male 73 284 6 25.92 4.320 
60 22 Male 65 136 7 4.473 0.639 
62 28 Female 62 177 850 568.8 0.669 
63 32 Male 68.5 170 210 540 2.571 
64 40 Female 64 159 90 918 10.200 
 
Table 11a. Tabulated values comparing the concentration of morphine-3-glucuronide 
analyzed in the decomposition fluid and liver. 
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Figure 41. Comparison of the morphine-6-glucuronide concentration in the liver and the 
blood. 
 
Table 12. Tabulated values comparing the concentration of morphine-6-glucuronide 
analyzed in the blood and liver. 









Times Higher in 
Liver than Blood 
1 23 Male 67 139 30 91.8 3.060 
3 24 Male 66 146 50 262.8 5.256 
4 21 Female 62 147 30 720.45 24.015 
24 45 Female 64 159 380 1633.5 4.299 
26 45 Male 73 231 60 303.75 5.063 
31 50 Male 70 221 15 11.25 0.750 
32 47 Female 62.5 176 60 19.44 0.324 
40 35 Female 63 181 5 13.68 2.736 
46 26 Female 64 116 6 9.9 1.650 
47 17 Female 62 146 60 577.8 9.630 
51 31 Male 70.5 259 130 238.5 1.835 
62 28 Female 62 177 160 166.5 1.041 
63 32 Male 68.5 170 30 499.5 16.650 












Table 13. Tabulated values comparing the concentration of norfentanyl analyzed in the 
blood and liver. 









Times Higher in 
Liver than Blood 
1 23 Male 67 139 6.4 16.155 2.524 
4 21 Female 62 147 0.27 2.0385 7.550 
12 56 Male 61 83 40.2 27.495 0.684 
13 28 Female 65 124 0.42 1.674 3.986 
15 24 Male 72.5 191 0.45 2.295 5.100 
16 36 Male 71 236 0.53 1.9485 3.676 
23 28 Male 71 191 2.2 15.03 6.832 
26 45 Male 73 231 1.2 4.3695 3.641 
27 28 Female 65.5 188 0.49 3.7395 7.632 
28 42 Female 62 138 5.7 35.955 6.308 
32 47 Female 62.5 176 1.5 4.2705 2.847 
33 29 Male 75 277 0.78 3.042 3.900 
34 32 Male 71.5 162 2.7 12.015 4.450 
35 29 Male 74.5 200 1.9 5.562 2.927 
36 36 Male 67 164 2.9 30.555 10.536 
37 33 Male 69.5 222 0.51 8.6175 16.897 
38 32 Male 69.5 330 0.97 6.228 6.421 
39 29 Female 64 153 6 0.106425 0.018 
40 35 Female 63 181 0.62 2.2995 3.709 
41 21 Male 70 319 0.51 3.3705 6.609 
42 44 Male 72 217 4.6 23.445 5.097 
43 33 Male 69 205 0.33 2.313 7.009 
44 49 Male 72.5 212 0.67 7.452 11.122 
46 26 Female 64 116 15.9 50.13 3.153 
47 17 Female 62 146 0.92 4.4325 4.818 
48 34 Male 72 168 13.2 41.895 3.174 
49 35 Male 63.5 207 1.4 10.305 7.361 
50 24 Male 72 164 4.2 31.41 7.479 
52 32 Male 74 163 6.4 38.97 6.089 
53 36 Male 73 284 0.77 5.1255 6.656 
54 46 Male 67 175 0.35 2.322 6.634 
55 35 Male 71 192 35.4 97.65 2.758 
56 31 Male 73 273 0.92 4.5675 4.965 
57 32 Male 69 208 1.2 4.635 3.863 
58 42 Male 68 205 2.6 12.96 4.985 
60 22 Male 65 136 5.4 22.05 4.083 







Figure 43. Comparison of the fentanyl concentration in the liver and the blood. 
 
Table 14. Concentration values of fentanyl analyzed in the blood and liver. 









Times Higher in 
Liver than Blood 
1 23 Male 67 139 16.6 31.905 1.922 
4 21 Female 62 147 3.1 44.595 14.385 
12 56 Male 61 83 112.2 85.14 0.759 
13 28 Female 65 124 21.2 210.15 9.913 
15 24 Male 72.5 191 1.9 7.1865 3.782 
16 36 Male 71 236 5.7 17.595 3.087 
18 27 Male 70 173 5.8 155.7 26.845 
22 47 Male 65 172 4.5 59.715 13.270 
23 28 Male 71 191 14.8 142.2 9.608 
26 45 Male 73 231 10.4 106.2 10.212 
27 28 Female 65.5 188 37.8 182.25 4.821 
28 42 Female 62 138 35.8 265.5 7.416 
29 22 Male 75.5 284 2.7 62.55 23.167 
32 47 Female 62.5 176 14.4 75.51 5.244 
33 29 Male 75 277 12.1 132.3 10.934 





35 29 Male 74.5 200 11.2 97.65 8.719 
36 36 Male 67 164 38.7 410.4 10.605 
37 33 Male 69.5 222 2.4 78.39 32.663 
38 32 Male 69.5 330 8.1 205.65 25.389 
40 35 Female 63 181 8.1 66.96 8.267 
41 21 Male 70 319 7.3 167.85 22.993 
42 44 Male 72 217 47.6 530.1 11.137 
43 33 Male 69 205 6.1 67.77 11.110 
44 49 Male 72.5 212 6.2 93.6 15.097 
46 26 Female 64 116 49.4 538.2 10.895 
47 17 Female 62 146 72 582.3 8.088 
48 34 Male 72 168 39.6 226.35 5.716 
49 35 Male 63.5 207 6 121.95 20.325 
50 24 Male 72 164 35.7 579.15 16.223 
52 32 Male 74 163 18.7 275.4 14.727 
53 36 Male 73 284 20.3 276.75 13.633 
54 46 Male 67 175 10 143.1 14.310 
55 35 Male 71 192 53 326.7 6.164 
56 31 Male 73 273 6.9 67.68 9.809 
57 32 Male 69 208 18.6 143.55 7.718 
58 42 Male 68 205 8.6 41.76 4.856 
59 37 Male 72 236 2.6 20.565 7.910 
60 22 Male 65 136 35.9 391.5 10.905 
61 40 Male 72 208 23.9 74.7 3.126 
63 32 Male 68.5 170 2.7 25.38 9.400 








Figure 44. Comparison of the norbuprenorphine concentration in the liver and the blood. 
 
Table 15. Tabulated values comparing the concentration of norbuprenorphine analyzed 
in the blood and liver. 









Times Higher in 
Liver than Blood 
28 42 Female 62 138 2.4 20.115 8.381 
32 47 Female 62.5 176 2.5 14.85 5.940 
36 36 Male 67 164 1.1 11.97 10.882 
42 44 Male 72 217 1.2 10.35 8.625 
53 36 Male 73 284 0.69 18.09 26.217 








Figure 45. Comparison of the buprenorphine concentration in the liver and the blood. 
 
Table 16. Tabulated values comparing the concentration of buprenorphine analyzed in 
the blood and liver. 









Times Higher in 
Liver than Blood 
28 42 Female 62 138 0.44 2.1015 4.776 
32 47 Female 62.5 176 1.7 4.581 2.695 
36 36 Male 67 164 0.78 1.566 2.008 
42 44 Male 72 217 0.2 3.6765 18.383 
53 36 Male 73 284 1.2 17.595 14.663 







The decomposition cases were sometimes higher in the blood than the liver, as 
shown in Figure 47, and post mortem redistribution (PMR) may have been a factor as to 
why this occurred. PMR may affect drug concentrations in the stomach and upper 
gastrointestinal tract depending on the drug concentration present at time of expiration, 
the volume of content present, temperature of the corpse, and time between death and 
sampling. According to (Pélissier-Alicot, 2003), PMR has been shown to increase the 
longer time has lapsed between death and autopsy, and has been shown to slow when the 
body is stored at -4°C. In the gastrointestinal tract, PMR has been found to redistribute 
drugs to surrounding tissues such as cardiac chambers, thoracic vessels, and sometimes 
the left lung, liver and inferior vena cava. PMR from the liver has been shown to 
redistribute drugs to the hepatic veins, inferior vena cava, right cardiac chambers, 
pulmonary vessels and peripheral vessels containing deoxygenated blood (Pélissier-
Alicot, 2003).  
Both Cases #9 and #10 were in a state of decomposition at the time the autopsy 
was performed. Case #10 had oxycodone measured at 7900 mcg/L in the decomposition 
fluid while no oxycodone was detected from the liver analysis for that case. If oxycodone 
was mainly present in the stomach of the individual for Case #10, PMR may have caused 
oxycodone to diffuse to surrounding organ tissues and vessels before extreme 
putrefaction occurred. In the event that the Case #10 was exposed to environmental 
temperatures which may have influenced the effect of PMR on that individual, it is worth 
noting that Case #10 expired on a warmer climate date of 7/30/14. Case #9 had an 





than in the liver for that case. Whether or not climate had an effect on PMR of the 







Figure 46. Hydromorphone, hydrocodone and oxymorphone concentrations in the liver 
compared to the concentrations in the decomposition fluid that was analyzed for Case 
#10. The biological samples collected were labeled as decomposition fluid instead of 
blood due to the decomposed state of the body at the time of autopsy.  
 
Table 17.  Tabulated values comparing the concentrations of hydromorphone, 
hydrocodone, oxymorphone, and oxycodone for Case #10. 
Component Case # Liver Concentration Decomposition Fluid Units 
Hydromorphone 10 46.485 10 mcg/L 
Hydrocodone 10 91.8 6 mcg/L 
Oxymorphone 10 281.25 210 mcg/L 







Figure 47. Morphine, morphine-3-glucuronide, and oxycodone concentrations in the 
liver compared to the concentrations in the decomposition fluid that was analyzed for 
Case #9. The biological samples collected were labeled as decomposition fluid instead of 
blood due to the decomposed state of the body at the time of autopsy.  
 
Table 18. Tabulated values comparing the concentrations of morphine, morphine-3-
glucuronide, and oxycodone for Case #9. 
Component Case # Liver Concentration Decomposition Fluid Units 
Morphine 9 334.8 1700 mcg/L 
Morphine-3-Glucuronide 9 8.289 140 mcg/L 







Figures 48-59 are pie charts displaying the percentage for each of the 12 opiates 
present in liver, blood or both liver and blood for the 64 cases analyzed. Tables 19-30 are 
the number of cases where those select opiates were present after blood and liver 
analysis. Morphine was present in the liver and blood analysis for almost half (45.31%) 
of the total cases analyzed. Four cases had morphine concentrations measured in the liver 
only, while only one case (Case #48) had a morphine concentration in the blood and not 
in the liver. Hydromorphone concentrations were present in the liver only for almost a 
quarter (23.44%) of the total cases, while only five percent of the total cases at 
concentrations in the liver and the blood. Codeine measurements were recorded in the 
liver only for over half the cases (57.81%) and 15.63% of the cases had concentrations in 
the liver and the blood. Only 9.38% of the total cases had hydrocodone concentration 
measurements in the liver only, while 14.06% had concentrations in the liver and the 
blood. Oxymorphone’s results were close to opposite that of hydrocodone; with 14.06% 
having concentration measurements in the liver only, and 7.81% of the cases having 
Oxymorphone concentration in the blood and the liver. Oxycodone measurements were 
present in the liver only for two cases, in the blood only for one case, and in the liver and 
the blood for seven cases. Almost a third of the cases (37.50%) had morphine-3-
glucuronide measurements in the liver only; also the same percentage of cases (37.50%) 
had concentrations in the liver and the blood. Morphine-6-glucuronide had measurements 
in the liver only for 39.06% of the cases analyzed, and concentration measurements in the 
liver and blood for 21.88% of the cases. Over a quarter (29.69%) of the cases analyzed 
had concentrations of norfentanyl in the liver only, and over half (57.81%) of the cases 





blood for over half the cases (65.63%), and 21.88% of the cases had concentrations in the 
liver only. norbuprenorphine had concentration measurements in the liver only for 
85.94% of the total cases analyzed, while 9.38% of the cases measured norbuprenorphine 
in the liver and in the blood. Lastly, buprenorphine had concentration measurements in 
over half the total cases (65.63%) in the liver only, while this component was measured 
in both the liver and the blood for 9.38% of the cases analyzed.   
Figure 60 shows the total number of measurements recorded for the 12 drugs 
analyzed in the liver and blood for 64 cases in the form of a pie chart. Table 31 contains 
the number of measurements, while Figure 60 displays the percentage of these 
measurements. Less than one percent (0.26%) of the opiates was measured in the blood 
only for the sixty four total cases analyzed, while 25.00% had opiate measurements 







Figure 48. Comparison of morphine concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and the number of cases that had 
no detectable morphine level.  
 
Table 19. The number of cases that had a value for morphine in the liver and blood, in 
the liver only, in the blood only and the number of cases that had no detectable morphine 
level.  
Morphine  
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 49. Comparison of hydromorphone concentration measurements present in both 
the liver and the blood, in the liver only, in the blood only and the number of cases that 
had no detectable hydromorphone level.  
 
Table 20. The number of cases that had a value for hydromorphone in the liver and 
blood, in the liver only, in the blood only and the number of cases that had no detectable 




No Value Liver Only Blood Only Sum of Cases 








Figure 50. Comparison of codeine concentration measurements present in both the liver 
and the blood, in the liver only, in the blood only and the number of cases that had no 
detectable codeine concentration.  
 
Table 21. The number of cases that had a value for codeine in the liver and blood, in the 
liver only, in the blood only and the number of cases that had no detectable codeine level.  
Codeine 
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 51. Comparison of hydrocodone concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and the number of cases that had 
no detectable hydrocodone level.  
 
Table 22. The number of cases that had a value for hydrocodone in the liver and blood, 
in the liver only, in the blood only and the number of cases that had no detectable 




No Value Liver Only Blood Only Sum of Cases 








Figure 52. Comparison of oxymorphone concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and the number of cases in which 
no oxymorphone was detected. 
 
Table 23. The number of cases that had a value for oxymorphone in the liver and blood, 
in the liver only, in the blood only, and the number of cases in which oxymorphone was 
not detected.  
Oxymorphone 
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 53. Comparison of oxycodone concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and the number of cases in which 
no oxycodone was detected.  
 
Table 24. The number of cases that had a value for oxycodone in the liver and blood, in 





No Value Liver Only Blood Only Sum of Cases 








Figure 54. Comparison of morphine-3-glucuronide concentration measurements present 
in both the liver and the blood, in the liver only, in the blood only and the number of 
cases in which no morphine-3-glucuronide was detected.  
 
Table 25. The number of cases that had a value for morphine-3-glucuronide in the liver 
and blood, in the liver only, in the blood only, and the number of cases in which no 
morphine-3-glucuronide was detected.  
Morphine-3-Glucuronide 
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 55. Comparison of morphine-6-glucuronide concentration measurements present 
in both the liver and the blood, in the liver only, in the blood only and those cases in 
which no morphine-6-glucuronide was detected.  
 
Table 26. The number of cases that had a value for morphine-6-glucuronide in the liver 
and blood, in the liver only, in the blood only, and those cases in which no morphine-6-




No Value Liver Only Blood Only Sum of Cases 








Figure 56. Comparison of norfentanyl concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and those cases in which no 
norfentanyl was detected.  
 
Table 27. The number of cases that had a value for norfentanyl in the liver and blood, in 
the liver only, in the blood only, and those cases in which no norfentanyl was detected. 
Norfentanyl 
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 57. Comparison of fentanyl concentration measurements present in both the liver 
and the blood, in the liver only, in the blood only and those cases in which no fentanyl 
was detected. 
 
Table 28. The number of cases that had a value for fentanyl in the liver and blood, in the 




No Value Liver Only Blood Only Sum of Cases 








Figure 58. Comparison of norbuprenorphine concentration measurements present in both 
the liver and the blood, in the liver only, in the blood only and those cases in which no 
norbuprenorphine was detected. 
 
Table 29. The number of cases that had a value for norbuprenorphine in the liver and 
blood, in the liver only, in the blood only, and those cases in which no norbuprenorphine 
was detected.  
Norbuprenorphine 
Liver & Blood No Value Liver Only Blood Only Sum of Cases 








Figure 59. Comparison of buprenorphine concentration measurements present in both the 
liver and the blood, in the liver only, in the blood only and those cases in which no 
buprenorphine was detected.  
 
Table 30. The number of cases that had a value for buprenorphine in the liver and blood, 





No Value Liver Only Blood Only Sum of Cases 








Figure 60. Comparison of total opiate concentration measurements of 12 different 
opiates (morphine, hydromorphone, codeine, hydrocodone, oxymorphone, oxycodone, 
morphine-3-glucuronide, morphine-6-glucuronide, norfentanyl, fentanyl, 
norbuprenorphine, and buprenorphine) present in both the liver and the blood, in the liver 
only, in the blood only and those cases in which none of the 12 opiates were detected. 
 
Table 31. The number of cases that had a value for each of the opiates in the liver and 
blood, in the liver only, in the blood only, and those cases in which none of the 12 opiates 
were detected.  
Total Opiates present in 64 Cases  
Liver & 
Blood 
No Value Liver Only Blood Only 
# of Measurements 
(12 drugs x 64 total cases) 







Five categories were used to classify the data from the 64 cases chosen for 
analysis. The categories consisted of classification using the case history and toxicology 
analysis from each sample. 
The five categories: 
1.) Case had known history of drug abuse 
2.) The case sample had only opiates (including fentanyl) present in toxicology 
analysis 
3.) Opiates and alcohol were present in the case sample 
4.) Opiate and other drugs (including marijuana) were present in toxicology analysis 
5.) Unclassified category; the case did not fit any of the categories 1-4.  
Figures 61-63 and Tables 32-34 display information based on these categories. Figure 
61 and its corresponding Table 32 display the percentage of each category compared to 
the total 64 cases. Over seventy percent (70.31%) out of the total number of cases had a 
history of drug abuse, 73.44% of the cases had opiates present with other drugs, 31.25% 
of the cases had opiates and alcohol present, and 18.75% of the cases had opiates present 
only at the time of analysis. Figure 62 and its corresponding Table 33 show the 
percentages of how frequent opiates and other drugs appear in the toxicology analysis of 
64 case samples. Almost half (46.88%) the number of cases sampled had opiates and 
other drugs present at the time of analysis. About a quarter (26.56%) of the cases had 
opiates, alcohol and other drugs present, 18.75% had opiates only, 4.69% had opiates and 
alcohol present, and 3.13% of the cases were unclassified. Figure 63 and Table 34 





have a drug abuse history and to those cases with an unknown history. Over half 







Figure 61. Percent of categories (1) – (5) out of the 64 total cases sampled. 
 
Table 32. Tabulated values from Figure 61. 
Categories Number of 
Cases 
% (of 64 cases) 
(1) History of drug abuse 45 70.31 
(2) Opiates/Fentanyl present only 12 18.75 
(3) Opiates & alcohol present 20 31.25 
(4) Opiates and other drugs present (including 
marijuana) 
47 73.44 








Figure 62. Drugs present in each category in relation to the 64 total cases. 
 






% (of 64 cases) 
(2) Opiates/Fentanyl present only 12 18.75% 
(3) Opiates & alcohol present only 3 4.69% 
(4) 
Opiates and other drugs present 
(including marijuana) 
30 46.88% 
(5) Unclassified 2 3.13% 
(3,4) 
Opiates, alcohol & other drugs 









Figure 63. Percent of 64 total cases that had a known history of drug abuse. 
 






% (of 64 cases) 
(1) History of Drug Abuse 45 70.31% 
 




For the cases where opiates and alcohol are present, Figure 64 compares the 
Ethanol levels measured in the blood, urine, vitreous humor, bile, and decomposition 
fluid. Table 35 corresponds to Figure 64 and contains the measured ethanol values for the 
cases which alcohol was involved. Case #25 had the highest ethanol concentration which 
was measured in the blood (0.307 % w/v) and vitreous humor (0.371 % w/v), while Case 





Methanol was present in the blood and vitreous humor of Case #31 at 0.336 and 
0.352 % w/v respectively. Methanol most likely was present from embalming fluid, as 
this was the only case that had been embalmed prior to sampling. Embalming fluid is a 




Figure 64. Ethanol concentration in blood, urine, vitreous humor, bile, and 





















1 0.068 0.019 -   - -  
4 0.017 -   -  - -  
7 0.011 -  0.021 0.015 -  
9  -  -  - 0.095  - 
10  -  -  - -  0.107 
11 0.012 0.122 0.029  -  - 
13  - 0.017 0.013  - 0.043 
14 0.226 0.292 0.273  -  - 
19 0.053 0.037  -  -  - 
22 0.123 0.155 0.136  -  - 
25 0.307 0.344 0.371  -  - 
44  - 0.094  -  -  - 
45 0.276 0.357 0.320  -  - 
46 0.010  -  - -   - 
52  - 0.030  -  -  - 
54 0.126 0.218 0.179  -  - 
55 0.030  -  -  -  - 
57 0.043  -  - 0.050  - 
61 0.036  -  -  -  - 
 
Looking at age, gender, and ethnicity as factors to the concentration difference of 
opiates in the liver and blood, most of the suspected overdose deaths were white males 







Figure 65. Number of cases versus the age of the individuals by intervals of 5 years. 
 
Table 36. Tabulated values from Figure 65. 























Figure 66. Comparing the number of male and female individuals by age (intervals of 5 
years). 
 
Table 37. Tabulated values from Figure 66. 
 Number of Cases 
Age Range Male Female 
0-4 0 1 
5-9 0 0 
10-14 0 0 
15-19 1 1 
20-24 8 1 
25-29 5 5 
30-34 11 1 
35-39 6 2 
40-44 3 3 
45-49 5 4 
50-54 2 2 
55-59 1 0 
60-64 0 1 
65-69 0 0 
70-74 0 0 













Table 38. Tabulated values from Figure 67 including number of cases for each ethnic 
group observed for the age of the individuals by intervals of five years, and the total 
number of cases for each ethnic group. 
 Number of Cases 
Age Range White Black Hispanic Other 
0-4 1 0 0 0 
5-9 0 0 0 0 
10-14 0 0 0 0 
15-19 1 0 1 0 
20-24 8 1 0 0 
25-29 10 0 0 0 
30-34 10 1 0 1 
35-39 7 0 1 0 
40-44 5 0 1 0 
45-49 8 0 1 0 
50-54 4 0 0 0 
55-59 1 0 0 0 
60-64 1 0 0 0 
65-69 0 0 0 0 
70-74 0 0 0 0 
75-79 1 0 0 0 
     
Total Number 
of Individuals: 







Figure 68. Comparing the number of males and females for each ethnicity observed in 
the 64 cases. 
 
Table 39. Tabulated values from Figure 68. 
 Number of Cases 
Gender White Black Hispanic Other 
Male 36 2 3 1 
Female 21 0 1 0 
 
 
The analytical method of this project has been comparative to the standard 
practices incorporated the toxicology validation process. Screening has been conducted in 
order to find out which is the best liver dilution for the widest range of drug detection. 
Sheep blood, human liver and beef liver matrices have been successful during analysis 





quantitated. Blood and liver calibrators and controls were incorporated in every 
extraction which would fulfill requirements of qualitative confirmation and identification 
analysis, as well as quantitative analysis.  
Bias analysis and interference studies could be further researched for this project. 
The 6-MAM disappeared from the chromatograph spectrum results after the liver 
samples were fortified with known concentrations, therefore was removed from the list of 
opiates analyzed in this thesis project. There was only one human liver that was screened 
negative for opiates that was used as a control before the project switched the liver 
controls to beef liver. However; even after the beef liver was used for control samples in 
the analysis, the beef liver samples were made up from only one cow’s liver. More 
human and cow control livers need to be analyzed to conclude that those liver matrices 
were not the reason for interrupting the 6-MAM during the extraction analysis, also to 
rule out the possibility that there may have been coexisting enzyme interference from 
those control livers. What happened to the 6-MAM during the extraction procedure? Did 
all or some of it convert to morphine? Did only the deuterated forms of morphine and 6-
MAM convert, or get deuterium cleaved off? Will newly developed opiates act similarly 
to 6-MAM during liver analysis? Many questions remain unanswered after completion of 
this project, and newly synthesized opiates continue to emerge from the market. Future 
research could deduce what happened to the 6-MAM after the extraction process was 










Cases chosen for screening were suspected overdose cases. Some blood (usually 
collected from the femoral artery), and liver samples were collected for further analysis. 
Immunoassays were performed to screen for opiates; the cases that screened positive for 
opiates and fentanyl were then subjected to further analysis using solid phase extraction, 
and then analyzed with the LC/MS/MS and each opioid was quantitated.  
From the data collected, it is very difficult to find correlations and reasons for 
why liver concentration was so variable and typically at higher levels than in blood for 
each of the cases analyzed. It’s difficult to determine if non-opiate drugs or alcohol 
present in some cases had interference with liver metabolism and the opiate quantitation 
results from the liver analysis. 
 Opioid metabolism may be influenced by genetic factors including age, gender, 
and ethnicity; or medical issues such as impaired liver function. Past studies have shown 
morphine, codeine, fentanyl and oxymorphone to metabolize at a slower rate in older 
individuals. Related opioid metabolism studies found oxycodone concentrations to be 
25% higher in women than in men after appropriate calculated dosages were 
administered to each individual based on body weight and known pharmacokinetics of 
these opioids (Smith, 2009). 
 Chinese individuals were found to produce less morphine from codeine and 





which was conducted to evaluate ethnic origin and pharmacodynamics effects of codeine 
and quinidine (Caraco Y., 1999).  
Different characteristics may have played a role in the correlation of drug 
concentrations in the blood compared to the liver including physique, the degree of 
putrefaction of the individual, sampling site and the amount of time between death and 
sampling contributing to post mortem redistribution (PMR) (Moriya, 2005; Pélissier-
Alicot, 2003). PMR may not be a significant factor in heroin fatalities based on a study of 
40 heroin fatality cases that measured PMR in heart and femoral blood concentration 
ratios for morphine and morphine 3- and 6-glucuronides to be close to one; however, 
another study of 42 heroin fatalities was measured to have heart and femoral blood 
concentration ratios of 1.8 for morphine. In the cases of morphine, hydromorphone, 
oxycodone, oxymorphone, codeine, hydrocodone, and fentanyl, past studies have shown 
that PMR may have contributed to the difference in drug concentration in the different 
sampling sites (Baselt, 2011).  
Opiates are broken down and processed by the liver. This process is conducted 
through phase one metabolism in the Cytochrome P450 pathway, by phase two 
metabolism of glucuronidation, or both phase one and phase two. Phase one metabolism 
involves the CYP3A4 and CYP2D6 enzymes. Both CYP3A4 and CYP2D6 are part of the 
Cytochrome P450 family of oxidizing enzymes, found in the intestines and liver, with the 
purpose of oxidizing xenobiotics in the body.  
Fentanyl and oxycodone are primarily metabolized by the CYP3A4 enzyme as 





drug interactions, and may affect how they are metabolized in the liver. The drugs which 
undergo phase two glucuronidation, such as morphine, oxymorphone, and 
hydromorphone, tend to have little involvement with the Cytochrome P450 pathway, and 
may have decreased risk of drug-drug interactions. However, the risk of 
pharmacodynamics drug-drug interactions still remains possible with all opioids when 
combining with other drugs, such as benzodiazepines, antihistamines, antagonistic drugs, 
or alcohol, and may result in toxicity (Smith, 2009).  
The liver’s function is to process blood as it circulates through the body, 
detoxifying harmful substances, such as drugs, and metabolizing nutrients. Enzymes in 
the liver help drive these chemical reactions and keep the liver functioning properly. 
Although opioids have rarely been found to cause liver injury in therapeutic doses, in 
cases of overdose, according to the U.S. National Library of Medicine, there have been 
cases of acute liver injury and toxicity. It may also be possible that liver injury is not 
directly related to the presence of opiates, but possibly the physical effects of opiate 
drugs, such as respiratory failure, cardiovascular collapse, shock and the absence of 
oxygen (U.S. National Library of Medicine, 2016). When death occurs, the liver cells 
containing these enzymes become damaged from lack of oxygen and nutrients, allowing 
drugs to diffuse outside the cells more easily (Moriya, 2005).  
We have established it is possible to quantitate opiates using liver samples for 
analysis. In most cases opiates showed up more frequently in liver than in blood analysis 
for these sixty four cases. It is possible that active enzyme metabolism in the liver has 
accounted for lower levels in the liver than in the blood in some cases. Heroin 





deacetylated in whole blood to form 6-MAM shortly after intravenous administration 
(Baselt, 2011). From the blood, 6-MAM is metabolized into morphine. Morphine is then 
further broken down in the liver to form glucuronides and metabolites before becoming 
excreted. Most of the opiates analyzed in this project metabolize in the liver; codeine 
metabolizes into morphine, morphine into morphine-3-glucuronide and morphine-6-
glucuronide, hydromorphone into hyromorphine-3-glucuronide, hydrocodone into 
hydromorphone, oxymorphone into oxymorphone-3-glucuronide, fentanyl into 
norfentanyl, buprenorphine into norbuprenorphine, as well as the metabolization of these 
drugs into all of their minor metabolites (Baselt, 2011).  
In most situations, the concentration of opiates in the liver was higher than levels 
found in the blood. In some cases, although no opiates were detected in the blood, levels 
were detected in the liver. Therefore, with the exception Case #48, where morphine 
appeared in the blood analysis and not the liver analysis, I propose that the liver may be a 







Bioavailability (Fb): The fraction of an administered dose of unchanged drug that 
reaches systemic circulation, the part of cardiovascular system carrying oxygenated blood 
away from the heart to the body and returns deoxygenated blood back to the heart. When 
a drug is administered intravenously the bioavailability is 100%. Drug administration by 
any other route is less than or equal to 100%.  
Decomposition Fluid: Accumulated fluid in the body cavity from the putrefaction of 
organs. Decomposition fluid is typically collected when there is no longer blood or 
anything of blood consistency available for collection due to decomposition and 
breakdown of body organs due to bacterial growth. 
δ-opioid receptor: Also identified as DOR (delta opioid receptor); δ-opioid receptors are 
7-transmembrane G protein-coupled receptors. They are “G” proteins because they bind 
the guanine nucleotides guanosine diphosphate (GDP) and guanosine triphosphate (GTP). 
When activated, these receptors produce analgesic effects, although there is still much 
unknown about the details of how exactly the δ receptor responds this way. 
First pass effect: Also known as “first pass metabolism,” an occurrence where the 
concentration of a drug is greatly reduced before it reaches the systemic circulation. 
Following oral administration of a drug, the drug gets absorbed by the digestive system 
and then is carried to the liver through the portal vein where it is subject to hepatic 
metabolism. This first pass metabolism in the liver greatly reduces the bioavailability of 
drugs due to incomplete absorption before the active drug travels to the rest of the 





Half-life (t ½): The time taken for half the drug dose to be eliminated or metabolized. 
Half-life may be influenced by many factors including metabolic and genetic factors.  
Hepatic metabolism: Chemical reactions that occur in an organism’s liver essential for 
survival including protein synthesis, production of biochemical necessary for digestion, 
the metabolism of xenobiotics including the detoxifications of drugs and toxins.  
HPC: High positive control for blood and liver listed in Appendix III, Tables 20 and 22. 
κ-opioid receptor: Also identified as KOR (kappa opioid receptor); A protein and a type 
of opioid receptor which binds opioid-like compounds in the brain and consequently the 
physical effects of these compounds are produced.   
Limit of Detection (LOD): The lowest quantity of a component that can be reliably 
distinguished from a “blank,” or the absence of that component, within a 
stated confidence limit. The confidence limit for LOD is generally 1%.  
Limit of Quantitation: The lowest concentration of an analyte that can be reliably 
measured by an analytical procedure where some predefined goals for bias and 
imprecision can be met.  
Lipophilicity: Refers to the ability of a chemical compound to dissolve in fats, oils, 
lipids, and non-polar solvents such as hexane or toluene. 
LPC: Low positive control for blood and liver listed in Appendix III, Tables 20 and 22. 
μ-opioid receptor: Also identified as MOR (mu opioid receptor); belongs to a class of 
opioid receptors which have a high affinity for enkephalins and beta-endorphin, but a low 





Opiate: a term generally used to label drugs that were derived from opium or chemical 
derivatives of opium. 
Opioid: A substance that acts on opioid receptors to produce morphine-like effects. They 
reduce the intensity of pain signals sensed in the brain and affect the areas of the brain 
responsible for controlling pain receptors and the stimuli responding to pain. This class of 
drugs is chemically similar to alkaloids found in opium poppies. 
P-glycoprotein: A permeability glycoprotein also identified as P-gp. It is a protein in the 
cell membrane that pumps foreign substances or toxins out of cells. In liver cells it can 
pump toxins/drugs into bile ducts, in the proximal tubule of the kidney it can pump 
substances into urine ducts, and in the blood-brain barrier it can pump toxins back into 
capillaries.  
Postmortem redistribution (PMR): Changes that may occur in the drug concentration 
of an individual after death. Antemortem drug concentrations present in an individual 
may not reflect those same concentration values in that individual postmortem.  
Respiratory depression: Also known as hypoventilation; a decrease in the ability to 
exhale and inhale. Occurs when ventilation is unable to provide a successful gas 
exchange and may cause increased carbon dioxide concentration and respiratory acidosis. 
Retention Time: The measured amount of time it takes a solute to travel through a 
chromatography column starting from the point at which the sample is injected until the 
time it is detected. Retention time includes the sum of the time spent in the stationary 






Transition (from Chromatogram): Measurement from analyzing the parent mass of the 
compound from the MS/MS fragmentation, and then monitoring the specific single 
fragment ion. The results are shown in relative intensity vs. retention time. For the 
LC/MS/MS quantitation conducted in this experiment, two transitions for each 
component were always measured.   
Upper Limit of Linearity: The highest concentration at which a further increase in 
concentration or mass flow-rate will still give an observable increase in detector signal. 
Volume of Distribution (Vd): The presumed volume needed to contain the total amount 
of an administered drug at the measured concentration that drug is observed in the blood 
plasma.  Vd is a theoretical measurement calculated as a ratio of the drug dose present in 
an individual and that individual’s blood plasma concentration.  
A = amount of drug in the body  
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Procedures Part A 
 
Create 1:3 homogenate solutions with liver matrix 
1) Weigh 5 grams of liver and add 10 milliliters of deionized water into a 50mL 
centrifuge test tubes plastic sample specimen bottle container with screw top. 
2) Use homogenizer Polytron PT 10-35, Dispersing and Mixing Technology by 
Kinematica, to make (1:3) homogenate solution: Blend together 5g Liver + 10 






Procedures Part B 
 
Opioid Quantitation by LC/MS/MS 
(Procedure from Erie County Toxicology Lab) 
First incorporated: 12/10/09 
Last update: 10/24/14 
I. Principle 
1.) Whole blood, plasma, and serum specimens are extracted for narcotic analgesics 
and their metabolites, along with their deuterated counterparts as internal 
standards by diluting and isolating the analytes on a C18 solid phase extraction 
column.  Elution with methanol allows for the recovery of all thirteen analytes in 
a single residue, which is subsequently evaporated, reconstituted, and subjected to 
an LC triple quadrapole, utilizing a MS/MS detection technique in the positive 
electrospray ionization mode.  
II. Specimen 
1) This analytical assay is designed to quantitate morphine, morphine-3-
glucuronide, morphine-6-glucuronide, 6-monoacetylmorphine, hydromorphone, 
oxymorphone, codeine, hydrocodone, oxycodone, fentanyl, norfentanyl, 





III. Reagents and Materials 
A. Standards 
1.) Table 1 (Standard Preparation) 
Name 








Final Standard Conc. 
      
Morphine Cerilliant M-005 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Morphine-3-Glucuronide Cerilliant M-031 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Morphine-6-Glucuronide Cerilliant M-096 1,000 1.0 ml 10.0 ml 100 mg/L MeOH/H2O 
Hydromorphone Cerilliant H-004 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Oxymorphone Cerilliant O-004 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
6-MAM Cerilliant A-009 1,000 1.0 ml 10.0 ml 100 mg/L in ACN  
Codeine Cerilliant C-006 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Hydrocodone Cerilliant H-003 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Oxycodone Cerilliant O-002 1,000 1.0 ml 10.0 ml 100 mg/L in MeOH 
Fentanyl Cerilliant F-002 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Norfentanyl Cerilliant  N-031 1,000 1.0 ml 100.0 ml 10 mg/L in MeOH 
Buprenorphine Cerilliant B-902 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Norbuprenorphine Cerilliant N-045 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
 
Table 2 (Working Stock Preparation) 





W.S."B" conc. W.S."C" conc. 







Morphine 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Morphine-3-Glucuronide 100 mg/L in MeOH 10.0 mg/L 1.0 ml 1.0 mg/L 0.1 mg/L 
Morphine-6-Glucuronide 100 mg/L MeOH/H2O 10.0 mg/L 1.0 ml 1.0 mg/L 0.1 mg/L 
Hydromorphone 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Oxymorphone 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
6-MAM 100 mg/L in ACN 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Codeine 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Hydrocodone 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Oxycodone 100 mg/L in MeOH 5.0 mg/L 0.5 ml 0.5 mg/L 0.05 mg/L 
Fentanyl 10 mg/L in MeOH 0.5 mg/L 0.5 ml 0.05 mg/L 0.005 mg/L 
Norfentanyl 10 mg/L in MeOH 0.5 mg/L 0.5 ml 0.05 mg/L 0.005 mg/L 
Buprenorphine 10 mg/L in MeOH 0.25 mg/L 0.25 ml 0.025 mg/L 0.0025 mg/L 






B. Internal Standards 
1. Table 5 (Deuterated Internal Standard Preparation) 
Name 








Final Control Conc. 
      
Morphine-d6 Cerilliant M-085 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Morphine-3-Glucuronide-d3 Cerilliant M-017 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Morphine-6-Glucuronide-d3 Cerilliant M-120 100 1.0 ml 10.0 ml 10 mg/L MeOH/H2O 
Hydromorphone-d6 Cerilliant H-049 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Oxymorphone-d3 Cerilliant O-003 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
6-MAM-d6 Cerilliant A-026 100 1.0 ml 10.0 ml 10 mg/L in ACN  
Codeine-d6 Cerilliant C-040 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Hydrocodone-d6 Cerilliant H-047 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Oxycodone-d6 Cerilliant O-007 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Fentanyl-d5 Cerilliant F-001 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Norfentanyl-d5 Cerilliant  N-030 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Buprenorphine-d4 Cerilliant B-901 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
Norbuprenorphine-d3 Cerilliant N-920 100 1.0 ml 10.0 ml 10 mg/L in MeOH 
 
2. Combination Internal Standard  
1) Add to a 100 ml volumetric flask 2.0 ml of morphine-d6, hydromorphone-
d6, oxymorphone-d3, 6-MAM-d6, codeine-d6, hydrocodone-d6, and 
oxycodone-d6 working stocks refer to Table 5, the concentration of these 
seven is 0.200 mg/L. 
2) Add to the same flask 0.2 ml of fentanyl-d5, norfentanyl-d5, 
buprenorphine-d4, and norbuprenorphine-d3 working stocks refer to Table 
5, the concentration of these four is 0.020 mg/L, dilute to the mark with 
methanol. 
3. Reagents and Supplies 





2) Acetonitrile, HPLC grade, J.T. Baker 
3) Formic Acid, reagent grade, Fluka Chemika 
4) Ammonium Formate, reagent grade, Fluka Chemika 
5) Concentrated Ammonium Hydroxide, reagent grade, J.T. Baker. 
6) 1M Ammonium Formate Solution. Add 6.3 grams of ammonium formate to a 
100 ml volumetric flask and dilute to the mark with deionized water. 
7) 0.01M Ammonium Carbonate buffer, pH 9.3.  Add 3.84 grams of  ammonium 
carbonate to 4.0 L deionized water, slowly add concentrated ammonium 
hydroxide until pH 9.3 is achieved, using a pH meter.  
8) Varian Bond-Elut LRC-C18, 200 mg solid phase extraction columns, or 
equivalent C18 SPE columns. 
9) Double Deionized Water 
10) Mobile Phase A, 10 mM ammonium formate, pH 3.0.  Add 10.0 ml of 1M 
ammonium formate solution to 950 ml deionized water and adjust pH to 3.0 
by drop wise addition of formic acid, using a pH meter, dilute to 1000 ml. 
with water.  
11) Mobile Phase B, 100% Acetonitrile. 
12) Reconstitution Solvent, 97/3, Mobile Phase A/Mobile Phase B. 





14) The Drugs and Deuterated Drugs used in this project were purchased from 
Cerilliant Corporation, 811 Paloma Dr. #A, Round Rock, TX 78665. Phone: 
(512) 238-9974 
15) The drug-free whole blood used throughout this study is Sheep blood which 
was obtained from Hemostat Laboratories, P.O. Box 790, Dixon, CA 95620, 
USA. Phone: (800) 572-6888 
IV. Instrumentation 
1) MS/MS detector, Applied Biosystems 3200 Qtrap 
2) Liquid Chromatograph, Shimadzu Prominence 20 Series binary pumps, degasser, 
auto sampler, column oven, and controller. 
3) Phenomenex Synergi Polar-RP 80A, 150 x 2.0 mm x 4.0 µm HPLC analytical 
column, or equivalent. 
4) Phenomenex Security Guard cartridges, Polar-RP 4.0 x 20 mm, guard column, or 
equivalent. 
5) UCT Positive Pressure Extractor. 
6) Zymark, TurboVap LV evaporator. 
V. Procedure 
A. Sample Preparation 





1) Prior to aliquoting whole blood specimen, invert tubes several times to 
ensure a homogeneous mixture of cells and serum. 
2) If the analyte levels are determined to exceed the concentration of the 
highest calibrator, a dilution of the specimen should be made using drug-
free whole blood or plasma. 
2. Calibrators 
1) Prepare calibrators in porcine whole blood of by adding the appropriate 
amounts of working stock standards “A”, “B”, or “C”, refer to Table 2.  It 
is preferable to add these solutions to the buffer solution, and then add 1.0 
ml of the blood matrix. 
a) STD 1 40 mcl of WS “C” 
b) STD 2 100 mcl of WS “C” 
c) STD 3 40 mcl of WS “B” 
d) STD 4 100 mcl of WS “B” 
e) STD 5 40 mcl of WS “A” 
f) STD 6 70 mcl of WS “A” 
g) STD 7 100 mcl of WS “A” 
2) Calibrator target values are listed below as mg/L concentrations, except 





Name STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 
        
Morphine 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Morphine-3-Glucuronide 0.004 0.010 0.04 0.10 0.40 0.70 1.00 
Morphine-6-Glucuronide 0.004 0.010 0.04 0.10 0.40 0.70 1.00 
Hydromorphone 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Oxymorphone 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
6-MAM 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Codeine 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Hydrocodone 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Oxycodone 0.002 0.005 0.02 0.05 0.20 0.35 0.50 
Fentanyl  ** 0.20 0.50 2.00 5.00 20.00 35 50.00 
Norfentanyl  ** 0.20 0.50 2.00 5.00 20.00 35 50.00 
Buprenorphine  ** 0.10 0.25 1.00 2.50 10.00 17.5 25.00 
Norbuprenorphine  ** 0.10 0.25 1.00 2.50 10.00 17.5 25.00 
 
3. Controls 
a) Positive, Low 
1) Prepared in-house in large batch lots from drug-free whole blood.  
2) Morphine, hydromorphone, oxymorphone, 6-monoacetylmorphine, 
codeine, hydrocodone, and oxycodone are targeted at 0.01 mg/L. 
Morphine-3-glucuronide and morphine-6-glucuronide are targeted at 
0.02 mg/L. Fentanyl, norfentanyl, buprenorphine, and 
norbuprenorphine are targeted at 1.0 mcg/L.   
b) Positive, High 
1) Prepared in-house in large batch lots from drug-free whole blood. 
2) Morphine, hydromorphone, oxymorphone, 6-monoacetylmorphine, 
codeine, hydrocodone, and oxycodone are targeted at 0.20 mg/L. 





0.40 mg/L. Fentanyl, norfentanyl, buprenorphine, and 
norbuprenorphine are targeted at 20.0 mcg/L 
c) Negative 
1) Drug-free whole blood is used for the negative control.  
B. Extraction 
1) Into respective, pre-labeled 16 X 125mm culture tubes add the following: 
a) 3.0 ml of 0.01M ammonium carbonate buffer, pH 9.3. 
b) Appropriate amounts of calibrator working stock, as listed above. 
c) 100 mcl of combination internal standard. 
d) One ml of blank blood for calibrators and controls. 
e) One ml of case bloods. 
f) Briefly vortex mix, approximately 30 seconds. 
2) Ultrasonicate all tubes for 10 minutes. 
3) Centrifuge tubes for 10 minutes @ 3600 rpm. 
4) Pre-condition the C18 SPE cartridges with 3 ml methanol, 3 ml deionized 
water, and 3 ml 0.01M ammonium carbonate buffer. 





6) Wash columns twice with 3 ml of 0.01M ammonium carbonate buffer, dry on 
high air flow for 10 minutes. 
7) Gravity drip 3 ml methanol to elute drugs into 13 x 100mm culture tubes. 
8) Evaporate solvent in the TurboVap set at 50 deg. C. using air flow. 
9) Reconstitute with 100 mcl of the reconstitution solvent. 
10) Injection amount varies according to the data acquisition method being used, 
refer to the appropriate method:  “OPS9.dam”, “OPS13.dam”, or 
“BupNBFentNF.dam”. 
C. Instrumental Parameters 
1) Chromatographic and mass spectral parameters are attached only for opioid 
acquisition method entitled “OPS13.dam”.  All related acquisition methods 
are clones of this one. 
2) Recalibrate method each time new calibrators are run. 
3) Position vials in auto-sampler tray and inject following this sequence: 
a) Negative Control 
b) Calibrators 
c) Carryover Check Sample, a re-injection of the Negative Control 
d) Low Control 





f) High Control 
D. Calculations 
1) Calibration and calculation of the acquired standard, control and unknown 
data uses the established quantitation application contained in the method, 
“OPS.qmf”.  This application contains peak integration parameters, curve type 
and weighting factor. 
2) Once all injections specified in the sequence have been made, create a results 
table from acquired data files, using the Quantitation Wizard application. 
3) Visually check the results table entries, noting analytes’ parameters, such as 
peak shape and integration, the calibration curve’s R value and calculated 
amounts.  Also, check individual case chromatograms and calculated amounts. 
4) If parameters check out, then proceed to printing out each calibrator, control 
and case file through the Reports template, “Erie County Medical. dot” 
5) Reports will include the following: 
a) Header information 
b) Results summary table listing internal standard’s and analyte’s ion 
transition data. 
c) Peak review pages showing a total ion chromatogram and extracted ion 
chromatograms for internal standards and analytes, calibration summary 





VI. Acceptance Criteria 
A. The Calibration 
1) The calibration should consist of a minimum of 5 consecutive, valid 
calibrators.  
2) One failed calibrator may be dropped from the upper and/or lower end of the 
calibration. 
3) The calibration range should bracket the unknown specimens.  If unknowns 
exceed the upper limit of linearity, then appropriate dilutions should be made 
to bring the sample back within the working range of calibrators. 
4) The correlation coefficient (r²) value should be 0.990 or better. 
B. Calibrators 
1) Peak shape should be symmetrically shaped and sharp without noticeable 
leading or trailing edges. 
2) Should read within ± 20 % of the weighed-in target value upon back-
calculation against the established calibration curve.  Note that the lowest 
calibrator tolerance is ± 30 %. 
3) Two transition pairs per analyte and internal standard are monitored and one 
ratio is determined.  Both transitions must be present (analyte and internal 
standard), the ratio of the quantifying transition to qualifying transition being 





4) Should be 70 % resolved with respect to the quantifying (target) peak, or 
better from the nearest potentially interfering peak. 
C. Controls 
1) The abundance of the internal standard of the negative and positive controls 
should be approximately equal. 
2) The negative control should read less than 25 % of the value of the lowest 
valid calibrator.  If it fails, then all samples positive for narcotic analgesics 
will be repeated. 
3) The measured value of the positive control must be within ± 20 % of the 
target value or the established value in the MultiQ control tracking software. 
4) The transition ratio criteria must be met, as stated above. 
5) If the positive control fails, then all positive samples will be retested. 
D. Specimens 
1) All criteria for the calibration as a whole, including calibrators and controls, 
should be met. 
2) Ion ratios for the analytes and internal standards in specimens should be 
within ± 20 % of the mean of all calibrators. 
3) The retention time for the unknowns must be within ± 3 % of the 





4) Values below the limit of detection will be reported as negative. 
5) Values above the upper limit of linearity should be appropriately diluted with 
negative whole blood and retested.  The result may also be reported as 
>ULOL (upper limit of linearity). 
6) If retesting of a specimen is necessary, the historic curve is valid provided that 
negative and 2 positive controls are run concurrently and pass acceptance 
criteria. Also, sufficient original internal standard solution must be available, 
and no alterations to the analytical instrument can be made. 
7) Signal to noise ratios must equal or exceed 10 for each compound to be 
reported. 
VII. Reporting Criteria 
1) Concentrations are reported in mg/L for the nine opiates and mcg/L for the 
other four (fentanyl, norfentanyl, buprenorphine, and norbuprenorphine). 
2) Morphine-3-glucuronide and morphine-6-glucuronide may be reported as “> 
1.0 mg/L” if they exceed the upper limit of linearity. 






Table 5 (LOD, LOQ, ULOL), (mg/L, mcg/L**) 
Name LOD LOQ ULOL 
    
Morphine 0.002 0.002 0.50 
Morphine-3-Glucuronide 0.004 0.004 1.00 
Morphine-6-Glucuronide 0.004 0.004 1.00 
Hydromorphone 0.002 0.002 0.50 
Oxymorphone 0.002 0.002 0.50 
6-MAM 0.002 0.002 0.50 
Codeine 0.002 0.002 0.50 
Hydrocodone 0.002 0.002 0.50 
Oxycodone 0.002 0.002 0.50 
Fentanyl  ** 0.20 0.20 50.00 
Norfentanyl  ** 0.20 0.20 50.00 
Buprenorphine  ** 0.10 0.10 25.00 
Norbuprenorphine  ** 0.10 0.10 25.00 
 
A. Interference Study 
1) The following compounds were ran as neat samples at a concentration of 5.0 
mg/L and found not to interfere by eluting at the same retention time or share 
transitions with the analytes of this assay:  dextrorphan, nalbuphine, 
nalorphine, ibugaine, dextromethorphan, and papaverine. 
2) These compounds share transition masses, but elute at different retention 
times than the analytes of this assay: 
a) Noroxycodone (rt = 7.26 min), shares with oxymorphone (rt = 6.49 min) 
mrm1 & mrm2. 
b) Norhydrocodone (minor peak rt = 7.60 min, major peak rt = 9.20 min), 
minor peak shares with hydromorphone (rt = 6.92 min) mrm1, major peak 





c) Noroxymorphone (rt = 7.15 min), shares with oxymorphone (rt-6.49 min) 
mrm1. 
d) Noscapine (rt = 11.27 min), shares with norbuprenorphine (rt = 10.6 min) 
mrm2. 
e) Naloxone (rt = 7.73 min), shares with 6MAM (rt = 8.36 min) mrm1 & 
mrm2. 
3) These compounds share transition masses and elute at the same retention time 
as the analytes of this assay 
a) Norcodeine (rt = 7.78 min), shares with codeine (rt = 7.79 min) mrm 1 and 
mrm 2 at the same retention time, due to manufacturing impurity of 
reference material (1% codeine). 
b) Normorphine (rt = 5.91 min), very slight sharing with morphine (rt = 5.91 
min) mrm 1 and mrm 2 at the same retention time, probably due to 
manufacturing impurity, as in the case of norcodeine. 
c) Thebaine (rt = 7.79 min), very slight sharing with codeine (rt = 7.79 min) 
mrm 1 and mrm 2 at the same retention time. 
d) Morphine-N-Oxide (minor peak rt = 5.92 min, major peak rt = 6.36 min), 
minor peak shares with morphine (rt = 5.91 min) mrm 1 and mrm 2 at the 
same rt, major peak shares with oxymorphone (rt = 6.49 min) mrm 1 and 





e) Codeine-N-Oxide (minor peak rt = 7.88 min, major peak rt = 7.88 min), 
minor peak shares with codeine (rt = 7.79 min) mrm 1 and mrm 2 at the 
same rt, major peak shares with oxycodone (rt = 8.31 min) mrm 1 and 
mrm 2, but at different rt. 
f) 10-Hydroxymorphine (rt = 5.91 min), shares with morphine (rt = 5.91 
min) mrm 1 and mrm 2 at the same rt. 
g) Diacetylmorphine (major peak rt = 8.36 min, minor peak rt = 5.91 min), 
major peak shares with 6-MAM (rt = 8.36 min) mrm 1 and mrm 2, at the 
same rt, minor peak shares with morphine (rt = 5.91 min) mrm 1 and mrm 
2, at the same rt.  Probably due to methanol instability of reference 
material. 
h) 6-Acetylcodeine (rt = 7.79 min), shares with codeine (rt = 7.79 min) mrm1 
and mrm 2, at the same rt.  Methanol instability could be a factor, here. 
i) Dihydrocodeine (rt = 8.59 min), very slight sharing with hydrocodone (rt 
= 8.59 min) mrm 1 and mrm 2, at the same rt. 
j) Ethylmorphine (minor peak rt = 5.88 min, major peak rt = 7.78 min), 
minor peak very slightly shares with morphine (rt = 5.91 min) mrm 1 and 
mrm 2, major peak slightly shares with codeine (rt = 7.79 min) mrm1 and 
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Backtracking Oxycodone & Hydrocodone in Case # 47 & 59, Respectively 
 
Table 1. Pharmacokinetic data for Oxycodone and Hydrocodone (Baselt, 2014). 
 
Oxycodone Hydrocodone 
Half-life (t ½) 3.4 – 8.8 hours 3.4 – 8.8 hours 
Volume of Distribution 
(Vd) 
3.3 – 4.7 L/Kg 3.3 – 4.7 L/Kg 
Bioavailability (Fb) 0.25 = 25% 0.25 = 25% 
Therapeutic Adult Oral 
Dose 
2.5 – 5 mg every 4-6 hours 
5 – 10 mg every 4-6 hours 
(45 mg suggested daily 
maximum) 
Therapeutic Extended 
Release Oral Dose 




1 – 10 mg every 4-6 hours  
Minimum Lethal Adult 
Dose  
100 mg 







Case #47  
Decedent:  Hispanic/Female/17 Years   62” 146 lbs. (66.2 Kg) 
Manner of Death:  Accident 
Cause of Death:  Acute mixed drug intoxication including fentanyl, heroin, cocaine, 
oxycodone, oxymorphone, hydroxyzine and lorazepam  
Date of Death 3/7/15 
Filled Oxycodone 3/5/15 
Original quantity 40 pills 
20 pills left 3/7/15 
5 mg / 325 mg (oxycodone/acetaminophen) 
Filled (1mg) Lorazopam 2/20/15 
Original quantity 30 pills  
14 pills left 3/7/15 
Filled Etodolac (NSAID-nonsteroidal anti-inflammatory) 3/5/15 
Original quantity 15 pills 
13 pills left 3/7/15 
The decedent had a history of asthma, left bicipital tendonitis and was a marijuana 
smoker.  She was seen January 2015 at the hospital for possible Methicillin-resistant 
Staphylococcus aureus (MRSA). The housemate is a known an IV heroin user. Decedent 
had her 4 wisdom teeth pulled on 3-5-15.  She received medication for pain.  Also 







Table 2. Opiate concentrations in the blood and liver for Case #47. 













 47 Codeine 
 
32.31 
 47 Hydrocodone 
 
0 
 47 Oxymorphone 4 2.088 0.522 




 47 Morphine-3-Glucuronide 330 990 3.000 
47 Morphine-6-Glucuronide 60 577.8 9.630 
47 Norfentanyl 0.92 4.4325 4.818 








Blood Level Oxycodone = 90 mcg/L = 0.09 mg/L 
Liver Level Oxycodone = 101.25 mcg/L = 0.10125 mg/L 
Blood Level Hydrocodone = 0 





Oxycodone Dosage Calculations 
5 mg each x 20 pills = 100 mg 
Probable dosage administered by decedent  = Vd x Weight x Blood level 
      = (1.8 L/kg) (66.2 kg) (0.09 mg/L) 
      = 10.72 mg oxycodone in decedent 
   Using blood concentration 
Intravenous delivery = 100% Fb = 10.72 mg 
Other route of administration = 25% Fb (multiply by 4 to backtrack) = 42.88 mg 
 
Probable dosage administered by decedent  = Vd x weight x Blood level 
      = (1.8 L/kg) (66.2 kg) (.10125 mg/L) 
      = 12.06 mg oxycodone in decedent  
   Using liver concentration 
Intravenous delivery = 100% Fb = 12.06 mg 






Decedent:  White/Male/37 Years   72" 236 lbs. (107.048 kg)  
Manner of Death:  Accident 
Cause of Death:  Acute mixed drug intoxication including fentanyl, cocaine, 
hydrocodone, alprazolam and pregabalin 
Date of Death 4/1/15 
Filled Hydrocodone 3/31/15 
Original quantity 90 pills 
0 pills left 4/1/15 
10 mg / 325 mg (hydrocodone/acetaminophen) 
Filled Alprazolam (Xanax) 3/31/15 
Original quantity 75 pills  
5 pills left 4/1/15 
Filled Zolpidem 3/31/15 
Original quantity 30 pills 
30 pills left 4/1/15 
Filled Lyrica 3/31/15 
Original quantity 90 pills 
89 pills left 4/1/15 
The decedent smokes 3/4 pack per day of cigarettes and he drinks occasional alcohol. 






Table 3. Opiate concentrations in the blood and liver for Case #59. 












 59 Hydromorphone 
 
0 
 59 Codeine 
 
0.8262 




 59 Oxycodone 
 
0 
 59 6-MAM 
 
0 
 59 Morphine-3-Glucuronide 
 
0 
 59 Morphine-6-Glucuronide 
 
0 
 59 Norfentanyl 
 
0.07983 




 59 Buprenorphine   0   
 
Blood Level Oxycodone = 0 
Liver Level Oxycodone = 0 
Blood Level Hydrocodone = 60 mcg/L = 0.06 mg/L 






Oxycodone Dosage Calculations 
10 mg each x 90 pills = 900 mg 
Probable dosage administered by decedent  = Vd x weight x Blood level 
= (3.30 L/kg) (107.048 kg) (0.06 mg/L) 
      = 21.20 mg oxycodone in decedent  
   Using blood concentration 
Intravenous delivery = 100% Fb = 21.20 mg 
Other route of administration = 25% Fb (multiply by 4 to backtrack) = 84.80 mg 
 
Probable dosage administered by decedent  = Vd x weight x Blood level 
      = (3.30 L/kg) (107.048 kg) (0.21825 mg/L) 
      = 77.10 mg oxycodone in decedent  
   Using liver concentration 
Intravenous delivery = 100% Fb = 77.10 mg 
Other route of administration = 25% Fb (multiply by 4 to backtrack) = 308.4 mg 
 
